{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red14\green86\blue140;
\red37\green37\blue37;
\red33\green33\blue33;
\red119\green119\blue119;
\red107\green107\blue106;
\red255\green255\blue102;
\red190\green190\blue252;
\red80\green80\blue80;
\red51\green51\blue51;
\red254\green254\blue0;
\red56\green124\blue43;
\red204\green204\blue204;
\red151\green151\blue151;
\red246\green246\blue246;
\red21\green137\blue21;
\red247\green247\blue247;
\red238\green238\blue238;
\red20\green93\blue164;
\red181\green79\blue104;
\red233\green233\blue233;
\red112\green112\blue112;
\red0\green114\blue54;
\red240\green240\blue240;
\red105\green105\blue105;
\red106\green144\blue39;
\red187\green187\blue187;
\red255\green255\blue174;
\red255\green248\blue96;
\red232\green233\blue232;
\red249\green249\blue249;
\red118\green118\blue118;
\red239\green122\blue2;
\red255\green194\blue211;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red204\green255\blue255;
\red61\green61\blue61;
\red188\green41\blue30;
\red190\green237\blue228;
\red236\green236\blue236;
\red127\green127\blue127;
\red149\green246\blue220;
\red227\green227\blue227;
\red71\green120\blue194;
\red102\green0\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Courier New;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid1594766977\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid-716388678}
}
{\*\listoverridetable
{\*\listoverride{\listid-716388678\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Ameritox, Ltd. v. Millennium Health, LLC, 88 F.Supp.3d 885 (2015)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
2015 Markman 728501
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_31}{\*\bkmkend co_document_31}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart Ie2f41dc4bb0411e4a795ac035416da91_Target}{\*\bkmkend Ie2f41dc4bb0411e4a795ac035416da91_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_31}{\*\bkmkend co_readingModeKC_31}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_31}{\*\bkmkend co_readingModeCitatorFlag_31}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ie2f41dc4bb0411e4a795ac035416da91&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_31}{\*\bkmkend co_readingModeNegativeTreatment_31}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I8c5d80e0e57211e79fcefd9d4766cbba/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI8c5d80e0e57211e79fcefd9d4766cbba%26ss%3D2035479688%26ds%3D2043433397%26origDocGuid%3DIe2f41dc4bb0411e4a795ac035416da91&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=20e873d6dc7a49b0b57732f8e6fa0421&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Procter & Gamble Company v. QuantifiCare Inc.
}
{\b0 \cf19 \f2 \i0 \fs16 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
N.D.Cal., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
December 19, 2017
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
88 F.Supp.3d 885
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court,
\par 
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
W.D. Wisconsin.
\par 
}
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
AMERITOX, LTD., and Marshfield Clinic, Inc., Plaintiffs,
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5034760622)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
MILLENNIUM HEALTH, LLC
}}}
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
No. 13\u8211\'3fcv\u8211\'3f832\u8211\'3fwmc.
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Signed Feb. 18, 2015.
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Filed Feb. 19, 2015.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_31}{\*\bkmkend co_synopsis_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Patent owner brought action alleging infringement of patents related to method for drug screening and compliance protocols for one sample of urine from a patient on a prescribed medication regimen. Defendant moved for summary judgment of non-infringement and invalidity as to both patents, and parties sought claim construction.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The District Court, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0181766401&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
William M. Conley
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, J., held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent claims were directed to an abstract idea;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
as an issue of first impression, patent contained sufficient inventive concept for patent eligibility;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent claims were not invalid under doctrine of indefiniteness; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent related to method for quantifying at least one metabolite in at least one biological sample was invalid for lack of enablement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Motion granted in part and denied in part.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \i0 \brdrt \brdrcf1 \brdrw20 \brdrs \fs20 \brdrr \brdrcf1 \brdrw20 \brdrs \brdrl \brdrcf1 \brdrw20 \brdrs \ri20 \qj \li20 \brdrb \brdrcf1 \brdrw20 \brdrs 
{\shading10000 \b1 \cf1 \cfpat35 \f2 \ri140 \i0 \qj \fs20 \li140 
{\b1 \cf19 \f2 \i0 \fs20 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Document/Ie2f41dc4bb0411e4a795ac035416da91/View/FullText.html?originationContext=document&transitionType=DocumentItem&vr=3.0&rs=cblt1.0&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Go to Markman Construed Terms
}
{\b1 \cf36 \f2 \i0 \fs20 
}}}
\par 
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_31}{\*\bkmkend co_attorneysAndLawFirms_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb1320 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_888_31}{\*\bkmkend co_pp_sp_7903_888_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*888
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0121202301&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
James P. Ulwick
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Kramon and Graham PA, Baltimore, MD, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0337247201&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam Louis Marchuk
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0422215101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Mark T. Smith
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0325160601&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Matthew F. Carmody
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321413601&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael R. Osterhoff
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0327877101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tiffany Patrice Cunningham
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328384001&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Timothy J. Carroll
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Perkins Coie LLP, Chicago, IL, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0326048901&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David Edwin Jones
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Perkins Coie LLP, Madison, WI, for Plaintiffs.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0272200001&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Robert Benjamin Wolinsky
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0392561701&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rebecca Cheryl Mandel
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0178504301&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Steven P. Hollman
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hogan Lovells U.S. LLP, Washington, DC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0275208201&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Arlene L. Chow
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0467282701&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Bonnie Chen
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hogan Lovells U.S. LLP, New York, NY, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0359110701&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Douglas Maynard Poland
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0353639701&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jennifer Lynn Gregor
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Godfrey & Kahn S.C., Madison, WI, for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_31}{\*\bkmkend co_opinion_31}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860948b1011ea80afece799150}{\*\bkmkend co_anchor_I109860948b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860968b1011ea80afece799150}{\*\bkmkend co_anchor_I109860968b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860968b1011ea80afece799150}{\*\bkmkend co_anchor_I109860968b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb800 
OPINION AND ORDER
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0181766401&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
WILLIAM M. CONLEY
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, District Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This patent dispute presents a question of first impression with respect to the subject matter eligibility of a urine or other biological sample for drug screening and compliance protocols under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, as well as related issues of enablement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The analysis is made more challenging by the state of flux in the treatment of competing goals inherent in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenges in recent years, and even in recent months. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_889_31}{\*\bkmkend co_pp_sp_7903_889_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*889
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1\u8211\'3f & BRCA2\u8211\'3fBased Hereditary Cancer Test Patent Litig.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d 755 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR Holdings, LLC v. Hotels.com, L.P.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d 1245 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 772 F.3d 709 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Of course, this debate reflects a broader tension in patent law between what is legitimate invention in need of the incentives of patent law and what is merely description of the natural world for which no further incentive is required than our desire to understand it better\u8212\'3fa tension recognized virtually from the outset of the American patent system. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1852194692&pubNum=0000780&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_780_159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_159" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Le Roy v. Tatham,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 55 U.S. 156, 159, 14 How. 156, 14 L.Ed. 367 (1852)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Justice Breyer\rquote s relatively recent opinion in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 attempts to reconcile the goal of ensuring that patents do not \u8220\'3fimpede innovation more than it would tend to promote it,\u8221\'3f and the axiomatic notion that \u8220\'3fall inventions, at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1293
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, Justice Breyer cautions that \u8220\'3ftoo broad an interpretation of the exclusionary principle could eviscerate patent law.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, plaintiffs Ameritox, Ltd., and Marshfield Clinic, LLC allege that defendant Millennium Health, LLC infringes two of their patents: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patents No. 7,585,680 (\u8220\'3fthe \u8242\'3f680 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, purporting to describe a method for drug screening and compliance protocols for one sample of urine from a patient on a prescribed medication regimen; and 7,785,895 (\u8220\'3fthe \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f), purporting to describe a similar method for one biological sample generally. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Am. Compl., Exs. A, B (dkt. 106\u8211\'3f1, 106\u8211\'3f2).) Defendant Millennium seeks summary judgment of non-infringement and invalidity as to both patents. (Dkt. # 126.) The parties also ask the court to construe various terms common to both patents, including most notably \u8220\'3fknown normative data\u8221\'3f and \u8220\'3fquantifying the concentration.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130); Pl.\rquote s Opp\rquote n (dkt. # 172).) For the reasons that follow, the court will deny Millennium\rquote s motion for summary judgment of non-infringement and invalidity with respect to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and grant the motion with respect to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, finding the patent invalid for lack of enablement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For many of the same reasons, the court finds the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is vulnerable to the application of the exclusionary principle under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, while the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is substantially less so.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860978b1011ea80afece799150}{\*\bkmkend co_anchor_I109860978b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860978b1011ea80afece799150}{\*\bkmkend co_anchor_I109860978b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
UNDISPUTED FACTS
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860978b1011ea80afece799150}{\*\bkmkend co_anchor_I109860978b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. The Licensing Agreement
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff Marshfield Clinic is a health care and research organization. Marshfield is also the assignee of the patents-in-suit from the inventors, Dr. Michael Larson and Dr. Thomas Richards.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff Ameritox Ltd. is in the field of pain medication monitoring, including a provider of urine drug testing (\u8220\'3fUDT\u8221\'3f) services. Ameritox is the exclusive licensee of the patents-in-suit pursuant to an exclusive license agreement between Ameritox and Marshfield dated March 15, 2010. In exchange for an exclusive license, Ameritox agreed to make certain royalty payments to Marshfield and to use good faith commercial efforts to develop, market, and sell a drug testing service based on the asserted patents.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860988b1011ea80afece799150}{\*\bkmkend co_anchor_I109860988b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860988b1011ea80afece799150}{\*\bkmkend co_anchor_I109860988b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. The Testing Protocols
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ameritox tests urine samples on behalf of doctors, nurses, and other health-care providers who prescribe pain medications to treat chronic pain. (Am. Compl. (dkt. # 106) \u182\'3f\u182\'3f 7.) Ameritox describes its UDT service as being able to \u8220\'3fhelp clinicians assess whether patients are correctly taking medications and whether the prescription 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_890_31}{\*\bkmkend co_pp_sp_7903_890_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*890
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 should be adjusted.\u8221\'3f (Dr. Paul J. Orsulak Infringement Report (\u8220\'3fOrsulak Infringement Rept.\u8221\'3f) (dkt. # 117) \u182\'3f\u182\'3f 27.) Healthcare professionals periodically use Ameritox\rquote s services to monitor drug levels in their patients in order to help assess their patients\rquote  therapeutic response to medications and adherence to the treatment plan, as well as to detect aberrant behaviors (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 illegal drug use) that may complicate treatment. (\u8242\'3f680 patent at 2:17\u8211\'3f20.)
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00112035479688_ID0EE4BG_31}{\*\bkmkend co_fnRef_B00112035479688_ID0EE4BG_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00112035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On May 16, 2011, Ameritox launched its current Rx Guardian CD service, which Ameritox asserts is based on the patents-in-suit.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00222035479688_ID0EF5BG_31}{\*\bkmkend co_fnRef_B00222035479688_ID0EF5BG_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00222035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The testing protocol for Rx Guardian CD has three phases. (Dr. Paul J. Orsulak Rebuttal Report (\u8220\'3fOrsulak Rebuttal Rept.\u8221\'3f) (dkt. # 118) \u182\'3f\u182\'3f 246\u8211\'3f56.) First, Ameritox performs a series of laboratory tests to detect and measure the amount of drug and drug metabolites in a patient\rquote s urine sample (the \u8220\'3fdetection\u8221\'3f steps, which are reflected in steps (a)-(d) of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Second, Ameritox \u8220\'3fnormalizes\u8221\'3f or \u8220\'3fadjusts\u8221\'3f urine drug levels for a patient\rquote s hydration status by determining the metabolite/
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ratio of the patient (the \u8220\'3fnormalization\u8221\'3f step, as reflected in step (e) of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00332035479688_ID0ET6BG_31}{\*\bkmkend co_fnRef_B00332035479688_ID0ET6BG_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00332035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Third, the Rx Guardian CD protocol compares a patient\rquote s normalized test results to a range of \u8220\'3fnormative data\u8221\'3f collected from other clinical patients on the same medication, who Marshfield carefully monitored to insure adherence to their prescribed opioid regimen (the \u8220\'3fdetermining\u8221\'3f step, as reflected in step (f) of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
By comparing the patient\rquote s normalized value to a range of values for other clinical patients believed to be prescribed and taking the same medication properly, the health care provider can better assess whether a patient is likely to be taking the prescribed drug in a manner consistent with the prescribed regimen. The three steps outlined above largely truncate the steps outlined in claim 1 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method for quantifying at least one metabolite in a biological sample comprising the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(a) providing one biological sample obtained from a patient on a prescribed medication regimen, wherein the sample comprises at least one test metabolite, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb200 
wherein in the sample is urine;
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(b) providing one set of known normative data specific to a reference metabolite, wherein the set of data is collected from a population that is on a prescribed medication regimen;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_891_31}{\*\bkmkend co_pp_sp_7903_891_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*891
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (c) contacting the biological sample with an analytical device;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(d) detecting the presence of at least one test metabolite in the biological sample with the device, wherein the device is capable of measuring the concentration of the test metabolite in the sample;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(e) normalizing the biological sample to adjust for changes in the patient\rquote s hydration status by determining the metabolite/creatinine ratio of the patient; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(f) quantifying the concentration of at least one test metabolite in the biological sample by comparing a ratio between the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite concentration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8242\'3f680 patent at 21:9\u8211\'3f32.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860998b1011ea80afece799150}{\*\bkmkend co_anchor_I109860998b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860998b1011ea80afece799150}{\*\bkmkend co_anchor_I109860998b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
III. The Specification, Prosecution History and Reexamination Certificates
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patents-in-suit have a priority date of August 28, 2003, and cover a method to monitor medication usage and to detect aberrant drug usage patterns, including overuse and under-use of prescribed medications. (\u8242\'3f680 patent at ABSTRACT.) The patents share the same specification, which states that adherence to a prescribed medication regimen is important to the success of most treatments, \u8220\'3fparticularly in patients in drug abuse or chronic pain programs.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:21\u8211\'3f24.) The specification further describes a number of sources used by health care professionals to monitor medication usage, including interviews with patients, medical records, pill counts, prescription monitoring programs, and testing of biological samples, such as urine. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:42\u8211\'3f48, 15:11\u8211\'3f15.) The specification also states that urine drug screens available in 2003 were limited to reporting a positive or negative result because of \u8220\'3fthe large amount of variability in urine drug concentrations, mostly due to variations in hydration and urinary output volume.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1:50\u8211\'3f53.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Both patents highlight problems with purely \u8220\'3fup or down\u8221\'3f test results. In particular, so long as patients took some amount of medication, their test results were positive and patients who overused or underused their medications continued to receive the same prescription:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To date, a test 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
is purely negative or positive as to the presence or absence of a drug metabolite in the urine.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Accordingly, it would be useful to develop a method to assess with confidence patient adherence to prescribed drug treatment regimens.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2:61\u8211\'3f3:3 (emphasis added).) In light of the problems in the prior art, the specification goes on to state that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[t]he method of the present invention enables improved clinical accuracy of protocols used in testing biological samples, such as, urine testing [and] the present invention can 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb200 
substantially improve the ability of a clinician to monitor and confirm whether a patient has been using the medication in a manner which is consistent with the prescription.
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3:17\u8211\'3f19, 4:50\u8211\'3f54) (emphasis added). The specification thus describes a method to \u8220\'3fimprove\u8221\'3f or \u8220\'3fenhance\u8221\'3f medication monitoring and seeks to identify aberrant drug use. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3:17\u8211\'3f19.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The description of the invention is also reflected in the prosecution history, including the inventors\rquote  statement that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Applicants developed a normative database for the drug metabolite hydration corrected ratio that allows statistical analysis of drug metabolite level in urine to determine if the medication is utilized in a manner consistent with the prescription or what the potential dose may have been.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_892_31}{\*\bkmkend co_pp_sp_7903_892_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*892
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Declaration of Rebecca C. Mandel (\u8220\'3fMandel Decl.\u8221\'3f), Ex. 24 (dkt. # 129\u8211\'3f24) pp. 14\u8211\'3f15); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also id.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. 17 (dkt. # 129\u8211\'3f17) p. 9.) By contrasting the invention with prior art references, the invention is better elucidated. For example, the inventors submitted to the Patent Office that the \u8220\'3fKell [reference] focuses on adulteration of the urine sample, whereas applicants\rquote  method [a] focuses on identification of the urine, [b] correction of hydration in order to reduce variability and then [c] comparison of that corrected drug metabolite to a normative database to identify appropriate or inappropriate\u8221\'3f drug use. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. 24 (dkt. # 129\u8211\'3f24) p. 15.) The inventors further represents that \u8220\'3fnone of the patent publications from the Kell portfolio anticipate or render the claims obvious.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Patent Office agreed with the inventors\rquote  submission leading to issuance of both patents. The patents also survived two more recent reexaminations, with the Patent Office issuing: the first reexamination certificates for the patents-in-suit in May and June 2013, leaving each of the challenged claims intact and issuing additional claims, and a second set of reexamination certificates on May and July 2014\u8212\'3fagain leaving each of the challenged claims intact. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See id.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. 1 (dkt. # 129\u8211\'3f1) pp. 27\u8211\'3f30; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. 2 (dkt. # 1292) pp. 26\u8211\'3f29.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609a8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609a8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609a8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609a8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
IV. Prior Art
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00442035479688_ID0E4PAI_31}{\*\bkmkend co_fnRef_B00442035479688_ID0E4PAI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00442035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12035479688_31}{\*\bkmkend co_anchor_B12035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 There are several references cited in the prosecution history (and by the parties themselves) that constitute prior art so well known by the \u8220\'3fscientific community\u8221\'3f at the time of the invention that it assists in determining whether the combination of elements in \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 constitute inventive concept. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (patent is invalid if any additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community). In reviewing these references, the court is mindful that when prior art is put into evidence\u8212\'3feither existing as part of the prosecution history or cited in expert reports\u8212\'3fthe reference must be considered in its entirety, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as a whole, including portions that would teach or steer away from the claimed invention. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1983151589&pubNum=0000350&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_350_1550&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1550" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
W.L. Gore & Assocs., Inc. v. Garlock, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 721 F.2d 1540, 1550 (Fed.Cir.1983)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
One of the most relevant prior art references in this case is the George Article. S. George & R.A. Braithwaite, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
A Pilot Study to Determine the Usefulness of the Urinary Excretion of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 and its Primary Metabolite (EDDP) as Potential Markers of Compliance in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 Detoxification Programs,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J. Analytical Toxicol.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Mar./Apr.1999, at 81\u8211\'3f85. (See Mandel Decl., Ex. 43 (dkt. # 129\u8211\'3f43).) The authors of the George Article investigate urinary excretion to determine whether \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or EDDP could be a simple and noninvasive marker of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 compliance.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 83.) Testing was specifically performed \u8220\'3fto try to resolve the issue of whether urinary excretion 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
could be
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 used 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
in place of plasma concentration
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as a mechanism to monitor compliance during 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 replacement therapy for opiate addiction.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added).)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The George Article was cited before the Patent Office, and it is also cited at length in Dr. Wu\rquote s expert report, opining that the patents were invalid on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
102
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_893_31}{\*\bkmkend co_pp_sp_7903_893_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*893
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 grounds.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00552035479688_ID0E6XAI_31}{\*\bkmkend co_fnRef_B00552035479688_ID0E6XAI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00552035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium further cites the George Article in support of the factual proposition that \u8220\'3fnormalizing urinary samples via metabolite/creatinine ratios [was] a routine and conventional practice\u8221\'3f at the time of the invention. (Def.\rquote s PFOFs (dkt. # 127) \u182\'3f 259.) The crux of the article, however, is best summarized by Ameritox\rquote s expert Dr. Orsulak who explains:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
One aim of the George article was to determine if quantitative urinary excretion data of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and EDDP may be used to distinguish between compliant and noncompliant subjects undergoing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 detoxification. (George article at 83.) The George article discloses two datasets from different patient populations. One patient population consisted of 14 control subjects. A second patient population consisted of 56 drug abusers, including those suspected of missing dosages or topping up from other sources of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (George article at 83.) The George article concludes, \u8220\'3fthere is too large of an interindividual variation to use urinary excretion concentrations of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 or EDDP as markers of compliance.\u8221\'3f (George article at 83.)
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Orsulak Rebuttal Rept. (dkt. # 118) \u182\'3f 59.)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As Dr. Orsulak points out, the George Article \u8220\'3fnever compares the results from any of the 56 drug abusers to the 14 control subjects. Rather, to the extent any comparison is made, the George article only discloses comparing a patient\rquote s test result to earlier results from that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
same
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patient.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at \u182\'3f 86 (emphasis added).) \u8220\'3fIn other words, the George article discloses a straight historical results analysis, without any 95% inclusion range being involved, nor is any comparison to a known normative database disclosed.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) Thus, the \u8220\'3fonly comparison disclosed in the George article is a single patient\rquote s test result to his/her own earlier test results.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) These facts were not squarely controverted in Dr. Wu\rquote s opinion, nor is there anything else in the record that puts them into dispute.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The George Article offers further insights into what was well known at the time of the claimed invention:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8226\'3f \u8220\'3fthere is too large of an interindividual variation to use urinary excretion concentrations of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 or EDDP as markers of compliance\u8221\'3f;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8226\'3f urinary excretion testing \u8220\'3fwould point to a lack of suitability of using urine concentrations of EDDP or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 as markers of compliance\u8221\'3f; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8226\'3f \u8220\'3fthe only reliable method available to monitor 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 compliance is the use of plasma 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 drug testing.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Mandel Decl., Ex. 43 (dkt. # 129\u8211\'3f43) 84\u8211\'3f85.) In each respect, the George Article supports a conclusion that at the time of the invention, blood testing was the only reliable method to determine whether a patient was complying with a prescribed drug regimen.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Another article that reflects the state of the art is the Haddow Article. Haddow, J., et al., 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Replacing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Creatinine Measurements
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 with Specific Gravity Values to Adjust Urine Cotinine Concentrations,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Clinical Chem
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 562 (1994). (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Expert Report of Roger L. Bertholf, Ph.D. (\u8220\'3fBertholf Rept.\u8221\'3f), Ex. H (dkt. # 209\u8211\'3f8).) The Haddow Article evaluates the use of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and specific gravity values in a study of environmental tobacco smoke exposure in non-smoking children with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iab17a50f475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
asthma
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 562.) Haddow uses a regression analysis 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_894_31}{\*\bkmkend co_pp_sp_7903_894_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*894
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the logarithm of urinary cotinine and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a population of 116 children who were not exposed to environmental tobacco smoke. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3f[A]lthough measuring 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine measurements
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to reflect hydration\u8221\'3f was known, Haddow teaches that it adds \u8220\'3fcomplexity and cost when such measurements are applied in routine and clinical practice.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) This is why \u8220\'3fspecific gravity (relative density) measurements in urine samples from children with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iab17a50f475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
asthma
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f were used to \u8220\'3fprovide information equivalent to that from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine measurements
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) Moreover, Haddow does not involve drug treatment or compliance with a prescribed drug regimen and no known normative database is developed. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 562\u8211\'3f64.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609b8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609b8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609b8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609b8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
V. The Skilled Addressee
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00662035479688_ID0EQJBI_31}{\*\bkmkend co_fnRef_B00662035479688_ID0EQJBI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00662035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the purposes of identifying a person of ordinary skill in the art, the court agrees with Dr. Orsulak that the \u8220\'3frelevant art of the subject matter claimed by the patents-in-suit is medication or therapeutic drug monitoring.\u8221\'3f (Orsulak Rebuttal Rept. (dkt. # 118) \u182\'3f 3.) Orsulak further opines that such a person would have a degree in a field \u8220\'3fsuch as medicine, biochemistry, biology, clinical health psychology, clinical laboratory sciences, clinical toxicology, or pharmacology and several years of work experience related to medication or therapeutic drug monitoring, including drugs-of-abuse testing or substance abuse testing.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) This characterization of the skilled addressee seems sensible; nothing in Millennium\rquote s materials alters this viewpoint; and the characterization is consistent with the field of the art applicable to the invention.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00772035479688_ID0EVLBI_31}{\*\bkmkend co_fnRef_B00772035479688_ID0EVLBI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00772035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609c8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609c8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609c8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609c8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
VI. The Claims of the \u8242\'3f680 and the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The disputed claims in suit\u8212\'3fspecifically claims 1, 2, 4\u8211\'3f7, 10 and 16\u8211\'3f18 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claims 1, 4\u8211\'3f5, 10\u8211\'3f12 and 14 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fgenerally disclose a series of six steps that culminate in a final comparison step between the drug collected from a patient\rquote s urine sample to \u8220\'3fknown normative data\u8221\'3f collected from a patient population. Neither party disagrees with this characterization. As such, the asserted independent claims of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (claims 1 and 4) and the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are represented below.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method for quantifying at least one metabolite in a biological sample comprising the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(a) providing one biological sample obtained from a patient on a prescribed medication regimen, wherein the sample comprises at least one test metabolite, wherein in the sample is urine;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(b) providing one set of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
known normative data
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 specific to a reference metabolite, wherein the set of data is collected from a population that is on a prescribed medication regimen;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(c) contacting the biological sample with an analytical device;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(d) detecting the presence of at least one test metabolite in the biological sample with the device, wherein the device is capable of measuring the concentration of the test metabolite in the sample;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_895_31}{\*\bkmkend co_pp_sp_7903_895_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*895
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (e) normalizing the biological sample to adjust for changes in the patient\rquote s hydration status by determining the metabolite/creatinine ratio of the patient; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(f) 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
quantifying the concentration of at least one test metabolite in the biological sample by comparing a ratio between the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite concentration.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8242\'3f680 patent at 21:9\u8211\'3f32 (terms in dispute have been bolded).)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
A method for quantifying at least one metabolite in at least one biological sample comprising the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(a) providing at least one biological sample obtained from a patient on a prescribed medication regimen, wherein the biological sample comprises at least one test metabolite;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(b) providing one set of known normative data specific to a reference metabolite, wherein the set of data is collected from a population that is on a prescribed medication regimen;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(c) contacting the biological sample with an analytical device;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(d) detecting the presence of at least one test metabolite in the biological sample with the device, wherein the device is capable of measuring the concentration of the test metabolite in the at least one biological sample;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(e) normalizing the biological sample to adjust for changes in the patient\rquote s hydration status by determining the metabolite/creatinine ratio of the patient; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(f) quantifying the concentration of at least one test metabolite in the biological sample by comparing a ratio between the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite concentration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8242\'3f895 patent at 20:56\u8211\'3f21:12.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With regard to the disputed terms, the parties\rquote  preferred constructions are summarized in the following table:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_tbl30_31}{\*\bkmkend co_anchor_tbl30_31}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
}
}
}
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt36 \clpadft3 \clpadr36 \clpadfr3 \clbrdrt \brdrcf30 \brdrw20 \brdrs \clbrdrb \brdrcf30 \brdrw20 \brdrs \clbrdrl \trql \clwWidth3360 \cellx3360 
\clpadt36 \clpadft3 \clpadr36 \clpadfr3 \clbrdrt \brdrcf30 \brdrw20 \brdrs \clbrdrb \brdrcf30 \brdrw20 \brdrs \trql \clwWidth3360 \cellx6720 
\clpadt36 \clpadft3 \clpadr36 \clpadfr3 \clbrdrt \brdrcf30 \brdrw20 \brdrs \clbrdrb \brdrcf30 \brdrw20 \brdrs \clbrdrr \trql \clwWidth3360 \cellx10080 
\intbl 
{\ri36 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \i0 \fs24 
{\b1 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Disputed Terms
\par 
}
}
}
}
{\b1 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b1 \cf1 \f4 \ri36 \ul0 \strike0 \i0 \ql \li36 \fs24 \sa0 \sb0 \intbl \cell \intbl 
{\ri36 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \i0 \fs24 
{\b1 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Plaintiff Ameritox\rquote s Preferred Construction
\par 
}
}
}
}
{\b1 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b1 \cf1 \f4 \ri36 \ul0 \strike0 \i0 \ql \li36 \fs24 \sa0 \sb0 \intbl \cell \intbl 
{\ri36 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \ri36 \i0 \ql \fs24 \li36 
{\b1 \cf1 \f4 \i0 \fs24 
{\b1 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Defendant Millennium\rquote s Preferred Construction
\par 
}
}
}
}
{\b1 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b1 \cf1 \f4 \ri36 \ul0 \strike0 \i0 \ql \li36 \fs24 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
}
}
}
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadt240 \clpadft3 \clpadr240 \clpadfr3 \clbrdrt \clbrdrb \brdrcf30 \brdrw20 \brdrs \clbrdrl \trql \clwWidth3360 \cellx3360 
\clpadt240 \clpadft3 \clpadr240 \clpadfr3 \clbrdrt \clbrdrb \brdrcf30 \brdrw20 \brdrs \trql \clwWidth3360 \cellx6720 
\clpadt240 \clpadft3 \clpadr240 \clpadfr3 \clbrdrt \clbrdrb \brdrcf30 \brdrw20 \brdrs \clbrdrr \trql \clwWidth3360 \cellx10080 
\intbl 
{\ri240 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u8220\'3fknown normative data\u8221\'3f (all
\par 
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
asserted claims)
\par 
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b0 \cf1 \f4 \ri240 \ul0 \strike0 \i0 \ql \li240 \fs24 \sa0 \sb0 \intbl \cell \intbl 
{\ri240 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf19 \f4 \i0 \fs24 
{\*\bkmkstart co_anchor_R12035479688_31}{\*\bkmkend co_anchor_R12035479688_31}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Plain and Ordinary Meaning
\par 
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b0 \cf1 \f4 \ri240 \ul0 \strike0 \i0 \ql \li240 \fs24 \sa0 \sb0 \intbl \cell \intbl 
{\ri240 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Known dose-specific data that is related to the population it is
\par 
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
intended to predict
\par 
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b0 \cf1 \f4 \ri240 \ul0 \strike0 \i0 \ql \li240 \fs24 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clpadt240 \clpadft3 \clpadr240 \clpadfr3 \clbrdrb \brdrcf30 \brdrw20 \brdrs \clbrdrl \trql \clwWidth3360 \cellx3360 
\clpadt240 \clpadft3 \clpadr240 \clpadfr3 \clbrdrb \brdrcf30 \brdrw20 \brdrs \trql \clwWidth3360 \cellx6720 
\clpadt240 \clpadft3 \clpadr240 \clpadfr3 \clbrdrb \brdrcf30 \brdrw20 \brdrs \clbrdrr \trql \clwWidth3360 \cellx10080 
\intbl 
{\ri240 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u8220\'3fquantifying the concentration of at least one test metabolite in the biological sample by comparing a ratio between the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite concentration\u8221\'3f (all asserted claims)
\par 
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b0 \cf1 \f4 \ri240 \ul0 \strike0 \i0 \ql \li240 \fs24 \sa0 \sb0 \intbl \cell \intbl 
{\ri240 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf19 \f4 \i0 \fs24 
{\*\bkmkstart co_anchor_R22035479688_31}{\*\bkmkend co_anchor_R22035479688_31}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Plain and Ordinary Meaning
\par 
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b0 \cf1 \f4 \ri240 \ul0 \strike0 \i0 \ql \li240 \fs24 \sa0 \sb0 \intbl \cell \intbl 
{\ri240 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ri240 \i0 \ql \fs24 \li240 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
To the extent that this term can be construed, it means: predicting the dosage taken by a patient from at least one test metabolite in the biological sample by comparing the ratio based on the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite
\par 
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
concentration
\par 
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
\u160\'3f
\par 
}
}
}\b0 \cf1 \f4 \ri240 \ul0 \strike0 \i0 \ql \li240 \fs24 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Millennium contends that the purpose of the patents is to quantify a specific dose. It argues that this purpose provides the proper context and is dispositive of what is meant by \u8220\'3fknown normative data.\u8221\'3f Similarly, with respect to the second disputed phrase\u8212\'3f\u8220\'3fquantifying the concentration\u8221\'3f\u8212\'3f 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_896_31}{\*\bkmkend co_pp_sp_7903_896_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*896
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
 Millennium argues in favor of a definition that specifically predicts the dosage of the test metabolite. Ameritox contends that neither of these disputed terms should be so confined. More specifically, Ameritox argues that Millennium\rquote s construction seeks to import limitations from the specification to deviate from the plain and ordinary meaning of the claim terms.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609d8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609d8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609d8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609d8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
OPINION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22035479688_31}{\*\bkmkend co_anchor_B22035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Analysis of patent infringement is a two-step process: \u8220\'3ffirst, the scope of the claims are determined as a matter of law, and second, the properly construed claims are compared to the allegedly infringing device to determine, as a matter of fact, whether all of the limitations of at least one claim are present, either literally or by a substantial equivalent, in the accused device.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002390499&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1323&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1323" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teleflex, Inc. v. Ficosa N. Am. Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 299 F.3d 1313, 1323 (Fed.Cir.2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032303378&pubNum=0004637&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_4637_844&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_844" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Split Pivot, Inc. v. Trek Bicycle Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 987 F.Supp.2d 838, 844\u8211\'3f47 (W.D.Wis.2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609e8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609e8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609e8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609e8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. Claim Construction
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32035479688_31}{\*\bkmkend co_anchor_B32035479688_31}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42035479688_31}{\*\bkmkend co_anchor_B42035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Claim terms \u8220\'3fare examined through the viewing glass of a person skilled in the art.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1313&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1313" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips v. AWH Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 415 F.3d 1303, 1313 (Fed.Cir.2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This provides an \u8220\'3fobjective baseline\u8221\'3f from which to begin the claim analysis. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004844816&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1116" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 381 F.3d 1111, 1116 (Fed.Cir.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The inquiry is assessed at the time of the invention, where the words of a claim \u8220\'3fare generally given their ordinary and customary meaning.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1313&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1313" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 415 F.3d at 1313
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52035479688_31}{\*\bkmkend co_anchor_B52035479688_31}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62035479688_31}{\*\bkmkend co_anchor_B62035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Because an \u8220\'3fordinary and customary\u8221\'3f meaning may not be readily apparent, and because \u8220\'3fpatentees frequently use terms idiosyncratically,\u8221\'3f courts look to the patent specification, the prosecution history, and pertinent extrinsic evidence to construe disputed claim terms. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1314&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1314" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1314
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The specification is typically considered the \u8220\'3fbest source for discerning the proper context of the claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1315&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1315" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 415 F.3d at 1315
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1966112594&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
United States v. Adams,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 383 U.S. 39, 49, 86 S.Ct. 708, 15 L.Ed.2d 572 (1966)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (describing as \u8220\'3ffundamental that claims are to be construed in the light of the specification\u8221\'3f). But when using the specification for the purposes of context, the skilled addressee must not improperly import a limitation from the specification into the claims themselves. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004844816&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1117" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Innova,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 381 F.3d at 1117
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (district court improperly read limitations from the specification into the claims); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1886180313&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
White v. Dunbar,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 119 U.S. 47, 51, 7 S.Ct. 72, 30 L.Ed. 303 (1886)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00882035479688_ID0ECFCI_31}{\*\bkmkend co_fnRef_B00882035479688_ID0ECFCI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00882035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72035479688_31}{\*\bkmkend co_anchor_B72035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Claim construction, therefore, requires a scalpel, not a sledgehammer because there is a thin line between 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
interpreting
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the claims in view of the specification and improperly 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reading
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 limitations from the specification into the claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004844816&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1117" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Innova,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 381 F.3d at 1117
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (considering the contrasting nature of these axioms to be a \u8220\'3flongstanding difficulty\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033875054&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Componex Corp. v. Electronics for Imaging, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. 13\u8211\'3fCV\u8211\'3f384\u8211\'3fWMC, 2014 WL 3556064, at *7 (W.D.Wis. July 18, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609f8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609f8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I1098609f8b1011ea80afece799150}{\*\bkmkend co_anchor_I1098609f8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. \u8220\'3fKnown Normative Data
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The term \u8220\'3fknown normative\u8221\'3f data is referenced in element (b) and element (f) of claim 1. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 21:28\u8211\'3f32.) The claim language expressly states that known normative data is \u8220\'3fcollected from a population that is on a prescribed medication regimen.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 21:16\u8211\'3f17.) In the abstract, known normative data is 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_897_31}{\*\bkmkend co_pp_sp_7903_897_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*897
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 collected from a population and used as the invention\rquote s baseline so it may be compared to a patient\rquote s normalized urine sample to determine whether there is compliance with a prescribed medication regimen.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Millennium contends that the term known normative data is known \u8220\'3fdose-specific data that is related to the population it is intended to predict.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 20.) Millennium contends that its proposed construction is the only one that reflects the express function of the invention. That function, Millennium contends, is to determine the exact dosage taken by a patient (and thereby determining whether a patient is complying with the prescribed dosage). Much of Millennium\rquote s construction is based on passages and examples in the specification, with particular emphasis placed on the following passages:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8226\'3f \u8220\'3fThis example describes how a drug metabolite/urine 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 ratio ... could be used to improve the ability of clinicians to predict appropriate use of prescribed medication, as well as detect and quantify inappropriate use.\u8221\'3f (\u8242\'3f680 patent at 6: 58\u8211\'3f62.)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
\u8226\'3f \u8220\'3fThe goal of the model was to be able to predict whether a patient had adhered to a prescribed dosage regimen.\u8221\'3f (\u8242\'3f680 patent at 9:65\u8211\'3f66.)
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Arguing that these passages reflect the purpose of the patents\u8212\'3f\u8220\'3fto predict the dosage taken by a patient\u8221\'3f\u8212\'3fMillennium contends that the claim language should be construed in accordance with that purpose. (Def.\rquote s Opening Br. (dkt. # 130) 24.) In addition, Millennium points to Example 1 for support. That example \u8220\'3fdescribes how a drug metabolite/urine 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ratio in patients ... could be used to improve the ability of clinicians to predict appropriate use of prescribed medication, as well as detect and quantify inappropriate use.\u8221\'3f (\u8242\'3f680 patent at 6:58:62.) Specifically, Example 1 describes the collection of UDT data from a population of seven patients on \u8220\'3fa specified 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 dosing regimen.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 7:7\u8211\'3f8.) Such data is reflected in Table III in each of the patents. Example 1 thus teaches a \u8220\'3fregression model for the prediction of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 intake,\u8221\'3f namely statistical analysis of \u8220\'3fknown normative data\u8221\'3f to predict the dosage of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 taken by a patient. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 9:31\u8211\'3f33.) From this, Millennium concludes that because the example is the \u8220\'3fonly detailed disclosure of the claimed invention in the patents-in-suit,\u8221\'3f it is instructive and should dictate claim meaning. (Def.\rquote s Opening Br. (dkt. # 130) 30.) The court, however, rejects Millennium\rquote s construction for several reasons.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82035479688_31}{\*\bkmkend co_anchor_B82035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 To succeed, Millennium ignores a \u8220\'3f \u8216\'3fbedrock principle\u8217\'3f of patent law that \u8216\'3fthe claims of a patent define the invention.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1312&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1312" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 415 F.3d at 1312
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026961295&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Thorner v. Sony Computer Entm\rquote t Am. LLC,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 669 F.3d 1362, 1365 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Millennium also faces an uphill battle in negating the general rule that claims are given their customary and ordinary meaning. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See Teleflex, Inc. v.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002390499&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1325&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1325" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
299 F.3d at 1325
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWe indulge a \u8216\'3fheavy presumption\u8217\'3f that a claim term carries its ordinary and customary meaning.\u8221\'3f). Specifically, courts should \u8220\'3fonly interpret a claim term more narrowly than its ordinary meaning under two circumstances: (1) when a patentee sets out a definition and acts as [its] own lexicographer, or (2) when the patentee disavows the full scope of a claim term either in the specification or during prosecution history.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027462516&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1330&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1330" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aventis Pharma SA v. Hospira, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 675 F.3d 1324, 1330 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotation omitted). \u8220\'3fThe standards for finding lexicography and disavowal are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
exacting.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033708203&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Hill\u8211\'3fRom Servs., Inc. v. Stryker Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 755 F.3d 1367, 1371 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Neither of these circumstances applies 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_898_31}{\*\bkmkend co_pp_sp_7903_898_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*898
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 here; nor is there any other canon of construction that allows Millennium to prevail.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
First,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium points to no definitive definition of \u8220\'3fknown normative data\u8221\'3f in the specification that supports its construction. When the skilled addressee turns to the specification the only definition that even comes close to the disputed phrase is the phrase: \u8220\'3fnormative database.\u8221\'3f (\u8242\'3f680 patent at 5:60\u8211\'3f65.) Notwithstanding the fact that \u8220\'3fnormative database\u8221\'3f is worded differently to \u8220\'3fknown normative data\u8221\'3f (the disputed term), Millennium\rquote s reliance on the former falls flat because the definition of \u8220\'3fnormative database\u8221\'3f simply states \u8220\'3fa collected set of data that is related to a specific population it is intended to predict.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 5:58\u8211\'3f60.) Contrary to Millennium\rquote s position, there is no mention of dose specific data or dose specific regimen. Because none of the definitions in the specification supply claim meaning, Millennium\rquote s proposed construction must be rejected. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027462516&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1330&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1330" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Hospira, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 675 F.3d at 1330
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031264023&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1301" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aria Diagnostics, Inc. v. Sequenom, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 726 F.3d 1296, 1301 (Fed.Cir.2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fTaken in context, this evidence does not support the trial court\rquote s interpretation, and certainly is not clear lexicography or disavowal.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Second,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 there is no claim disavowal in the prosecution history. The best that Millennium can muster is the following passage:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Applicants developed a normative database for the drug metabolite hydration corrected ratio ... to determine if the medication is utilized in a manner consistent with prescription or what the [patient\rquote s] potential dose 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
may
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 have been.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(Def.\rquote s Opening Br. (dkt. # 130) 29 (emphasis altered).) Millennium\rquote s reliance on this passage is deficient for much the same reason as the first: the term normative database is used instead of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
actual
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 disputed term that is subject to the litigation (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 known normative data). But even if the proper disputed phrase had been referenced above, the passage still supplies little to support Millennium\rquote s position. Indeed, the passage creates more questions than answers due to the permissive language used. Said another way, the word \u8220\'3fmay\u8221\'3f preceded by the phrase \u8220\'3fmanner consistent with the prescription\u8221\'3f is hardly verbiage that disavows the full scope of a claim term. Neither phrase is \u8220\'3fexacting.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033708203&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Stryker Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 755 F.3d at 1371
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While Millennium argues that a person skilled in the art would equate the phrase \u8220\'3fmanner consistent with prescription\u8221\'3f as meaning dose specific data, the court is not so convinced. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033708203&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1372&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1372" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1372
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fDisavowal requires that the specification or prosecution history make clear that the invention does not include a particular feature.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Third,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium provides no meaningful discussion for how references in the specification and the prosecution history narrowed claims scope to circumvent prior art. More specifically, nothing in the specification indicates that \u8220\'3fdose specific data\u8221\'3f is an essential feature of the claimed invention over the prior art. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004121243&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_906&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_906" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim Co. v. Medrad, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 358 F.3d 898, 906\u8211\'3f09 (Fed.Cir.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (distinguishing cases where the court narrowly construed an otherwise broad claim term).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To be fair, Millennium does argue that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[d]uring prosecution of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, the patentees specifically used the known dose-specific element of \u8220\'3fknown normative data\u8221\'3f to distinguish the claimed invention from the prior art. Specifically, the patentees asserted that \u8220\'3f[a]pplicants are able to not only accurately analyze the level of drug metabolite, within a specific patient, but more importantly, across individuals on the same drug and drug dose.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_899_31}{\*\bkmkend co_pp_sp_7903_899_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*899
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Def.\rquote s Opening Br. (dkt. # 130) 29 (emphasis omitted).) But, in the next sentence, and without supplying any further analysis, Millennium concludes that its construction \u8220\'3fmakes sense.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) The problem with Millennium\rquote s argument is simple: it lacks depth. While an argument based on prosecution estoppel would tend to have traction in most cases, Millennium\rquote s argument here is only limited to the above mentioned passage\u8212\'3fperhaps because it had little to work with in the first place. This limited analysis contrasts starkly with a recent case in this court, finding that a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
functional
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 definition was deliberately used by the patentees to avoid prior art. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033875054&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Componex Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2014 WL 3556064, at *7
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that during the litigation, the definition could not be abandoned in order to expand the scope of its \u8220\'3fpatent beyond what was previously claimed\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, no effort is made by Millennium to show that the inventors deliberately abandoned claim scope to traverse prior art, let alone refer to the specific prior art references that inventors were seeking to distinguish in the prosecution history to provide a basis for estoppel.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Without such analysis, Millennium\rquote s construction is far less persuasive. It is rejected accordingly. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998248882&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Spectrum Int\rquote l, Inc. v. Sterilite Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 164 F.3d 1372, 1379\u8211\'3f80 (Fed.Cir.1998)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fBy distinguishing the claimed invention over the prior art, an applicant is indicating what the claims do not cover.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Fourth,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium\rquote s argument fares no better when it points to examples in the specification to construe the claims. Specifically, Millennium argues that known normative data must mean \u8220\'3fdose specific\u8221\'3f data because Example 1 expressly supplies such meaning when read in the context of both patents. To succeed in this argument, Millennium must again overcome the presumption that favors plain and ordinary meanings of claim terms. In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teleflex,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Federal Circuit held that the district court erred when it imported a limitation from the specification, thereby straying from the ordinary meaning of the claim term \u8220\'3fclip\u8221\'3f by requiring a \u8220\'3fclip\u8221\'3f to have a \u8220\'3fsingle pair of legs,\u8221\'3f even though the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
only
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 embodiment in the specification disclosed a clip having a single pair of legs. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002390499&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1327&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1327" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
299 F.3d at 1327\u8211\'3f28
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Thus, in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teleflex,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the only embodiment in the specification supported the alleged infringer\rquote s position\u8212\'3fand the Federal Circuit still reversed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Unlike 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teleflex, multiple
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 embodiments are provided in the \u8242\'3f680 and \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 895 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although Example 1 does provide a dose specific embodiment, other embodiments are not so confined. Ameritox directed the court to the following passage from the specification that is illustrative:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The method [of the invention] is carried out by contacting the biological sample with a device capable of distinguishing between the test metabolite and a reference metabolite; detecting the presence of at least one test metabolite in a biological sample; and quantifying the concentration of at least one test metabolite in a biological sample by comparing a ratio between a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
set of unknown data
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 from the test metabolite versus a set of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
known normative data
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 specific to the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reference metabolite.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 The method of the present invention enables improved clinical accuracy of protocols used in testing biological samples, such as urine testing.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8242\'3f680 patent at 3:6\u8211\'3f18 (emphasis added).)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Even if 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
all
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the embodiments described known normative data as including dose-specific data (and they do not), Millennium\rquote s construction would still stray impermissibly from the plain and ordinary meaning of the claim term. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teleflex
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states as much. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002390499&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1325&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1325" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
299 F.3d at 1325
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031264023&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1301" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aria Diagnostics, Inc. v. Sequenom, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 726 F.3d 1296, 1301 (Fed.Cir.2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ( \u8220\'3f[E]ven if a specification has only one embodiment, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_900_31}{\*\bkmkend co_pp_sp_7903_900_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*900
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 its claims will not be confined to that example \u8216\'3funless the patentee has demonstrated a clear intention to limit the claim scope using words or expression of manifest exclusion or restriction.\u8217\'3f \u8221\'3f (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004121243&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_906&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_906" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 358 F.3d at 906
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011260129&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MBO Labs., Inc. v. Becton, Dickinson & Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 474 F.3d 1323, 1334 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A] fundamental principle of patent claims construction is that the court should not read limitations from the specification into the claim language; the specification can only be used to limit a claim if there has been \u8216\'3fa clear disclosure that the patentee intended the claims to be limited.\u8217\'3f \u8221\'3f (internal citation omitted)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As the passage explains, the use of the phrase known normative data is deliberately juxtaposed with unknown data from the test metabolite. The juxtaposition is used to demonstrate that while the invention does require known normative data to provide a baseline from which to improve clinical urine testing, that data need not be a specific dosage.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Indeed, had the patentee sought to limit the claim language in this way, it would have elected to do so. The lack of a limitation in the claims reinforces the case against a restrictive reading of the disputed term. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003685773&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1088&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1088" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ACTV Inc. v. Walt Disney Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 346 F.3d 1082, 1088 (Fed.Cir.2003)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[T]he analytical focus of claim construction must begin, and remain centered, on the language of the claims themselves.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
More specifically, element (b) of claim one expressly states: \u8220\'3fproviding one set of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
known normative data
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 specific to a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reference metabolite,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 wherein the set of data is collected from a population that is on a prescribed medication regimen.\u8221\'3f (\u8242\'3f680 patent at 21:16\u8211\'3f17 (emphasis added).) Language in the embodiment above tracks key language in claim 1 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as demonstrated here, only strengthening Ameritox\rquote s construction-
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 data that is not unknown, and certainly not limited to data that is dose specific. The view is fortified by the fact that when inventors knew how to specify dose in one of the patents\rquote  embodiments (Example 1), they did so. And by not doing the same in the claims, this tends to end the debate over the disputed term. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Compare
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 9:65\u8211\'3f66 (specification using the term \u8220\'3fprescribed dosage regimen\u8221\'3f), 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
with id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 21:16\u8211\'3f1 (claim 1 using the phrase \u8220\'3fprescribed medication regimen\u8221\'3f).)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, because of the claim language conforms with embodiments cited in the specification and because there is no clear scope disavowal, the court rejects Millennium\rquote s proposed construction.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a08b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a08b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a08b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a08b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. \u8220\'3fQuantifying\u8221\'3f (step (f))
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Millennium argues that interpretation of step (f) is guided by the \u8220\'3fintended purpose of the patents,\u8221\'3f which is \u8220\'3fto predict or determine drug dosage taken by a patient.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 44.) It follows, Millennium contends, \u8220\'3fthat any construction of the claim\u8212\'3fspecifically step (f)\rquote s comparison between the patient\rquote s ratio to the known normative data from a population\u8212\'3fmust reflect the stated goal.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 45.) The court disagrees.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As an initial matter, the purpose of the patents is far broader than what Millennium maintains. Millennium\rquote s entire construction is predicated on the flawed assumption that that the patents\rquote  sole objective is to identify the specific dose of a patient.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00992035479688_ID0EXNDI_31}{\*\bkmkend co_fnRef_B00992035479688_ID0EXNDI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00992035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
9
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This purpose is too narrowly 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_901_31}{\*\bkmkend co_pp_sp_7903_901_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*901
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 drawn because the patents\rquote  specification and prosecution history directs one skilled in the art to an invention that allows \u8220\'3fanalysis of drug metabolite level in urine to determine if the medication is utilized in a manner consistent with the prescription or what the potential dose may have been\u8221\'3f\u8212\'3fa broader goal. (Mandel Decl., Ex. 24 (dkt. # 129\u8211\'3f24) pp. 14\u8211\'3f15; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also id.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. 17 (dkt. # 129\u8211\'3f17) p. 9.) Instead of being dose specific, the method of the \u8220\'3finvention enables improved clinical accuracy of protocols used in testing biological samples, such as, urine testing.\u8221\'3f (\u8242\'3f680 patent at 3:17\u8211\'3f19.) This, as the inventors say, \u8220\'3fcan substantially improve the ability of a clinician to monitor and confirm whether a patient has been using the medication in a manner which is consistent with the prescription.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4:50\u8211\'3f54.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When compared with pre-existing testing protocols, the state of the art sought to determine \u8220\'3fa positive or negative result as to the presence or absence\u8221\'3f of a drug. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2:66\u8211\'3f67.) In contrast, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides a method to \u8220\'3fimprove\u8221\'3f and \u8220\'3fenhance\u8221\'3f medication monitoring and identify aberrant drug use. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3:17\u8211\'3f19.) While Millennium is correct in saying that courts look to the object or purpose of the invention, such analysis must be examined in the totality so to guard against the claims being pulled in different ways by the different embodiments in the specification.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1886180313&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
White,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 119 U.S. at 51\u8211\'3f52, 7 S.Ct. 72
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (patents are not \u8220\'3fnose[s] of wax which may be turned and twisted in any direction by merely referring to the specification\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Millennium further contends that each of the examples indicate specific embodiments of the invention that seek to predict dosage based on the comparison applied in step (f). For reasons similar to that stated above, this argument must also be rejected. Two aspects of the claimed invention include: (1) \u8220\'3fdetermine if the medication is utilized in a manner consistent with the prescription\u8221\'3f and (2) \u8220\'3fdetermine ... what the [patient\rquote s] potential dose may have been.\u8221\'3f (Mandel Decl., Ex. 24 (dkt. # 129\u8211\'3f24) pp. 14\u8211\'3f15; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3:20\u8211\'3f27.) The first aspect can be accomplished with or without definitive prediction of dosage. While the second aspect uses dose-specific data, the patent stops short of claiming that the invention definitively predict ingested dose, simply stating that the invention may be used to approximate what the \u8220\'3fpotential\u8221\'3f dose \u8220\'3fmay have been.\u8221\'3f The multiple aspects of the patent demonstrate that the asserted claims do not require dose-specific data. As such, the asserted patents are prime examples for why the Federal Circuit \u8220\'3frepeatedly warn[s] against confining the claims to [the] embodiments\u8221\'3f of the specification. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1323&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1323" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 415 F.3d at 1323
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002390499&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1325&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1325" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teleflex,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 299 F.3d at 1325
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim language that is narrow would only limit the patents to determining potential or approximate doses, not whether medication is being used in a manner consistent with the prescription. The claim encompasses both these embodiments. A broader purpose afforded to the patented invention reflected in the actual claim language ensures a plurality of embodiments that fall within the claims. This broad reading of the claims is further fortified by the fact that the word \u8220\'3fdose\u8221\'3f and \u8220\'3fdose-prediction\u8221\'3f appear nowhere in the asserted claims. Like the previous disputed term, the lack of a limitation in the claims reinforces the case against a restrictive reading of the disputed term here. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003685773&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1088&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1088" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ACTV,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 346 F.3d at 1088
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[T]he analytical focus of claim construction must begin, and remain centered, on the language of the claims themselves.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, Millennium\rquote s request that the court read a definitive dose-prediction limitation into the asserted claims finds no 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_902_31}{\*\bkmkend co_pp_sp_7903_902_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*902
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 support in the actual claim language. Because of this, the court will decline Millennium\rquote s invitation to insert a limitation when canons of construction suggest otherwise. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006931523&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1323&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1323" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 415 F.3d at 1323
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011260129&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MBO Labs., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 474 F.3d at 1334
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a18b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a18b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a18b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a18b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. Motion for Summary Judgment on Invalidity and Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Summary judgment is warranted under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 56
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fif the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed.R.Civ.P. 56(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The moving party bears the burden of showing that the facts material to the motion are not in dispute. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132677&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Celotex Corp. v. Catrett,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 477 U.S. 317, 323, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The nonmoving party may not avoid summary judgment merely by showing that some facts are in dispute; rather, it must establish that there are factual issues that might affect the outcome of the suit under governing law. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132674&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson v. Liberty Lobby, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 477 U.S. 242, 247\u8211\'3f48, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although the court must \u8220\'3ftake all facts and reasonable inferences in the light most favorable to\u8221\'3f the nonmoving party, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032671306&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Helman v. Duhaime,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 742 F.3d 760, 761 (7th Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the nonmoving party must still come forth with enough evidence to support a reasonable jury verdict in its favor, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018075063&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1137&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1137" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Delta Consulting Grp., Inc. v. R. Randle Constr., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 554 F.3d 1133, 1137 (7th Cir.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Summary judgment is \u8220\'3fnot a dress rehearsal or practice run,\u8221\'3f but the \u8220\'3fput up or shut up moment\u8221\'3f in which a party must show what evidence it has to convince a trier of fact to accept its version of events. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013160858&pubNum=0004637&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_4637_760&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_760" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nichols v. Nat\rquote l Union Fire Ins. Co. of Pittsburgh, PA,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 509 F.Supp.2d 752, 760 (W.D.Wis.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999104074&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_504&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_504" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Schacht v. Wis. Dep\rquote t of Corr.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 175 F.3d 497, 504 (7th Cir.1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because a patent is presumed valid, Millennium must prove invalidity by clear and convincing evidence. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2242&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2242" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Microsoft Corp. v. i4i Ltd. P\rquote ship,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3fU.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 131 S.Ct. 2238, 2242, 180 L.Ed.2d 131 (2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, for Millennium to succeed in the instant motion for summary judgment, it must present clear and convincing evidence from which a reasonable jury could find that the patent is invalid. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007290116&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1149&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1149" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nystrom v. TREX Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 424 F.3d 1136, 1149 (Fed.Cir.2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035306745&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CertusView Techs., LLC v. S & N Locating Servs., LLC,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. 2:13cv346, 2015 WL 269427, at *14 (E.D.Va. Jan. 21, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B010102035479688_ID0EI6DI_31}{\*\bkmkend co_fnRef_B010102035479688_ID0EI6DI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B010102035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
10
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a28b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a28b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a28b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a28b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92035479688_31}{\*\bkmkend co_anchor_B92035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act defines patentable subject matter: \u8220\'3fWhoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The section defines four categories of patentable inventions: processes, machines, manufactures, and compositions of matter. Despite these broad categories, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 encompass all products of human effort and discovery. For example, \u8220\'3flaws of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_903_31}{\*\bkmkend co_pp_sp_7903_903_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*903
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 nature, physical phenomena, and abstract ideas\u8221\'3f constitute ineligible subject matter and are not patentable. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. All of these exceptions are well established. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Parker v. Flook,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 437 U.S. 584, 599, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Stewart, J., dissenting); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gottschalk v. Benson,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 409 U.S. 63, 67, 93 S.Ct. 253, 34 L.Ed.2d 273 (1972)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Funk Bros. Seed Co. v. Kalo Inoculant Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 333 U.S. 127, 68 S.Ct. 440, 92 L.Ed. 588 (1948)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1939125969&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MacKay Radio & Tel. Co. v. Radio Corp. of Am.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 306 U.S. 86, 94, 59 S.Ct. 427, 83 L.Ed. 506 (1939)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1852194692&pubNum=0000780&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Le Roy v. Tatham,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 55 U.S. 156, 14 How. 156, 14 L.Ed. 367 (1853)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a38b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a38b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
1. Recent Legal Developments
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The validity of many business and software patents has been called into question following the Supreme Court\rquote s decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corporation v. CLS Bank International,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B011112035479688_ID0EKJAK_31}{\*\bkmkend co_fnRef_B011112035479688_ID0EKJAK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B011112035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
11
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Patents in the biotechnology and diagnostic fields have also come under scrutiny since the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision was handed down in June of 2014, with some having already been found invalid. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1\u8211\'3f & BRCA2\u8211\'3fBased Hereditary Cancer Test Patent Litig.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d 755 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As a result, courts and commentators are understandably seeking more concrete contours in the application of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which instead of acting like the coarse \u8220\'3ffilter\u8221\'3f it once was, now arguably imposes a \u8220\'3fhigher bar,\u8221\'3f invalidating numerous patents in district courts and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
inter partes
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 proceedings before the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034719813&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_978&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_978" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Patent Office. 
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cal. Inst. of Tech.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 59 F.Supp.3d at 978\u8211\'3f79, 2014 WL 5661290, at *2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_720&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_720" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 772 F.3d at 720
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, this court will follow the Supreme Court\rquote s admonition in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to \u8220\'3ftread [ ] carefully\u8221\'3f in applying this reinvigorated exclusionary principle to the patents at issue here. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Supreme Court articulated a \u8220\'3fframework\u8221\'3f for determining whether 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is met. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1296\u8211\'3f97
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). First, a court determines \u8220\'3fwhether the claims at issue are directed to one of those patent-ineligible concepts\u8221\'3f\u8212\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 whether the claims are directed to laws of nature, natural phenomena, and abstract ideas. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Second, if the claims are directed to patent-ineligible concepts, the process sought to be patented must include an additional element or a combination of additional elements that constitute \u8220\'3finventive concept\rquote  \u8221\'3f\u8212\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fan element 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
or
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 combination of elements that is \u8216\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948116775&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Funk Bros.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 333 U.S. at 130, 68 S.Ct. 440
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIf there is to be invention from [a discovery of a law of nature], it must come from the application of the law of nature to a new and useful end.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before applying the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework to the patents-in-suit, a review of the Supreme Court\rquote s recent decisions in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 which similarly dealt with drug level testing and diagnostic patents, as well as some of the post-
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Federal Circuit decisions 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_904_31}{\*\bkmkend co_pp_sp_7903_904_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*904
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 may be helpful. In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the patents-in-suit concerned the use of thiopurine drugs in the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39e7bac475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
autoimmune diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In particular, doctors knew that such drugs could be helpful in treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibdaf9fd0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Crohn\rquote s disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=injury&entityId=Iba86e8a8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
drugs\rquote  toxicity
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or effectiveness could be measured relative to how thiopurine metabolized in the body. Before the filing date of the invention, however, it had been difficult for doctors \u8220\'3fto determine whether for a particular patient a given thiopurine dose was too high, risking harmful side effects, or too low, and so likely ineffective.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1295" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1295
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Said another way, the scientific community did not know the precise correlations between metabolite levels and likely harm or ineffectiveness.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court found that this is where the patent addressed a need, with claims directed to \u8220\'3fprocesses embodying researchers\rquote  findings that identified these correlations with some precision.\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B012122035479688_ID0EPWAK_31}{\*\bkmkend co_fnRef_B012122035479688_ID0EPWAK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B012122035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
12
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 While the Court had not yet adopted the two-step framework later set out in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis certainly reflected the first step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework while suggesting the second. Specifically, upon coming to the conclusion that the patent was directed to ineligible subject matter, the Court asked rhetorically: \u8220\'3fWhat else is there in the claims before us?\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This provided the segue to what is now the second part of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework: the search for inventive concept. At that juncture, the representative claim was divided into an \u8220\'3fadministering\u8221\'3f step, a \u8220\'3fdetermining\u8221\'3f step, and a \u8220\'3fwherein\u8221\'3f step. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To begin, the Supreme Court held that the \u8220\'3fadministering\u8221\'3f step did not supply inventive concept because the \u8220\'3fstep simply refers to the relevant audience, namely doctors who treat patients with certain diseases with thiopurine drugs.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The \u8220\'3fdetermining\u8221\'3f step was treated with equal disdain because it simply \u8220\'3ftells the doctor to determine the level of relevant metabolites in the blood, through whatever process the doctor ... wishes to use.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Justice Breyer found 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
that
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step \u8220\'3fnothing more [than] well-understood, routine, conventional activity previously engaged in by scientists who work in the field.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 To support this conclusion, Justice Breyer cited admissions in the patent itself that the processes for determining the level of metabolites in a patient\rquote s blood were \u8220\'3fwell known in the art.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1298.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B013132035479688_ID0EE4AK_31}{\*\bkmkend co_fnRef_B013132035479688_ID0EE4AK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B013132035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
13
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As to the \u8220\'3fwherein\u8221\'3f step in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Supreme Court found those clauses simply \u8220\'3ftell the relevant audience about the laws while 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_905_31}{\*\bkmkend co_pp_sp_7903_905_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*905
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 trusting them to use those laws appropriately where they are relevant to their decision-making (rather like Einstein telling linear accelerator operators about his basic law and then trusting them to use it where relevant).\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Next, the Court addressed the patentability of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
combination
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of these steps. The Court found that \u8220\'3fto consider the three steps as an ordered combination adds nothing to the laws of nature that is not already present when the steps are considered separately.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Justice Breyer\rquote s opinion distinguished the decision from the Court\rquote s previous holding in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 450 U.S. 175, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To Justice Breyer, nothing in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 suggests that the steps of the claimed process or their combination \u8220\'3fwere in context obvious, already in use, or purely conventional,\u8221\'3f as had been found to be true with respect to the claimed process in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Parker v. Flook,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 437 U.S. 584, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B014142035479688_ID0EXCBK_31}{\*\bkmkend co_fnRef_B014142035479688_ID0EXCBK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B014142035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
14
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1299&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1299" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1299
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[I]t was nowhere suggested that all the steps [in Diehr\rquote s invention], or at least the combination of those steps were ... conventional.\u8221\'3f). Because of this, Justice Breyer concluded that \u8220\'3fthe patentees [in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ] did not seek to pre-empt the use of [the] equation, but sought only to foreclose from others the use of that equation in conjunction with all of the other steps in their claimed process.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotations omitted). In Justice Breyer\rquote s view, these other steps apparently added to the formula in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 something that had significance in terms of patent law\rquote s objectives\u8212\'3f\u8220\'3fthey transformed the process into an 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
inventive application
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the formula.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1299&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1299" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1299
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added.).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, Justice Breyer expressly addressed the risk of preemption, stating that \u8220\'3fthe Court has repeatedly emphasized the concern that patent law [must] not inhibit further discovery by improperly tying up the future use of laws of nature.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For this reason, Justice Breyer cautioned against patents that would \u8220\'3fforeclose[ ] more future invention than the underlying discovery could reasonably justify.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B015152035479688_ID0EUIBK_31}{\*\bkmkend co_fnRef_B015152035479688_ID0EUIBK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B015152035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
15
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Justice Breyer concluded that, as in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Benson,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 where the claimed mathematical formula had \u8220\'3fno substantial practical application except in connection with a digital computer,\u8221\'3f the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were overly broad because they \u8220\'3fdid not differ significantly from a claim that just said apply the algorithm.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Benson,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 409 U.S. at 71, 93 S.Ct. 253
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Since 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Federal Circuit has continued to develop the standard for what constitutes patentable subject matter. In particular, two recent decisions provide insights into what constitutes an \u8220\'3finventive concept\u8221\'3f under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice\rquote s
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 second step. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR Holdings, LLC v. Hotels.com, L.P.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d 1245 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, for example, the Federal Circuit 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_906_31}{\*\bkmkend co_pp_sp_7903_906_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*906
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reviewed patents \u8220\'3fdirected to systems and methods of generating a composite web page that combines certain visual elements of a host website with content of a third-party merchant.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1248&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1248" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
773 F.3d at 1248
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Judge Chen found that the patents were directed toward more than an abstract idea or fundamental business practice; they solved a problem particular to the internet. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1257&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1257" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1257
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fInstead of the computer network operating in its 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
normal, expected manner
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ... the claimed system generate[d] and direct[ed] the visitor to [a] hybrid web page that presents product information from the third-party and visual \u8216\'3flook and feel\u8217\'3f elements from the host website.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1258&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1258" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1258\u8211\'3f59
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Because the patents were directed toward solving a new problem, particular to the internet, and solved the problem beyond \u8220\'3froutine or conventional use of the internet,\u8221\'3f Judge Chen found that the patents were significantly more than just an abstract idea. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1259&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1259" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1259
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B016162035479688_ID0ETRBK_31}{\*\bkmkend co_fnRef_B016162035479688_ID0ETRBK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B016162035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
16
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
More recently, the Federal Circuit examined whether gene sequences known as BRCA1 and BRCA2 could overcome a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1\u8211\'3f & BRCA2\u8211\'3fBased Hereditary Cancer Test Patent Litig.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d 755 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The case involved Myriad Genetics, Inc. suing Ambry Genetics Corporation for infringement of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,753,441
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,747,282
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the 1990s, Myriad had discovered the precise locations and sequences of the BRCA1 and BRCA2 genes, mutations linked to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic5e75ac4475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hereditary breast and ovarian cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Myriad was then able to determine the typical sequences of the genes most often found in humans (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the \u8220\'3fwild-type\u8221\'3f sequence for each), as well as mutations that depart from these two sequences. Some mutations were harmless, while other mutations correlated with an increased likelihood of developing particular 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. By testing for the presence of these mutations, doctors could determine whether a patient is particularly prone to developing breast or ovarian 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As in the present case, the method claims involved comparison steps. Ambry, however, argued that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was directly on point because these claims \u8220\'3fsimply identif[ied] a law of nature (the precise sequence of the BRCA genes, and comparisons of wild-type BRCA sequences with certain mutations of those gene sequences found in the test subject) and appl[ied] conventional techniques.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_762&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_762" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 762
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In a slight twist, the Federal Circuit declined to decide whether 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 applied to the process patents \u8220\'3fbecause the method claims suffer[ed] from a separate infirmity: they recite[d] abstract ideas.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In analyzing claims 7 and 8, the court noted that both were similar and dependent from claim 1. In applying the two-step framework of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the court dissected the claims to a first set of paragraphs, \u8220\'3fwhich describe the comparison of wild type genetic sequences with the subject\rquote s genetic sequence and correspond to the first step of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f and the second set of paragraphs, \u8220\'3fwhich describe the techniques to be used in making the comparisons and correspond to the second step of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_763&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_763" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 763
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holding that the first paragraphs\u8212\'3fthe comparison step\u8212\'3famounted to an abstract idea, the court turned to the second paragraphs in claim 7 and claim 8, respectively. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The court found that the second paragraph of claim 7 described the way in which the \u8220\'3fsequences are compared: they are compared by 1) hybridizing a BRCA gene probe and 2) detecting the presence of a hybridization product.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 764
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Similarly, the court said that \u8220\'3fclaim 8 requires 1) amplification of the BRCA1 gene 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_907_31}{\*\bkmkend co_pp_sp_7903_907_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*907
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 2) sequencing of the amplified nucleic acids.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The court found that \u8220\'3fclaims 7 and 8 do not add \u8216\'3fenough\u8217\'3f to make the claims as a whole patent-eligible.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This holding was predicated on the unchallenged finding by the district court that the elements of the second paragraphs of claims 7 and 8 \u8220\'3fset forth well-understood, routine and conventional activity engaged in by scientists at the time of Myriad\rquote s patent applications.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quotations omitted). The court concluded:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The second paragraphs of claims 7 and 8 do nothing more than spell out what practitioners 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
already knew
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fhow to compare gene sequences 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
using routine, ordinary techniques.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Nothing is added by identifying the techniques to be used in making the comparison because those comparison techniques were the well-understood, routine, and conventional techniques that a scientist 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
would have thought of
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 when instructed to compare two gene sequences.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Just as Justice Breyer tethered the notion of well-understood, conventional steps to \u8220\'3factivity already engaged in by the scientific community\u8221\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 tethered the notion of well-understood, conventional steps to \u8220\'3ftechniques that a scientist would have 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
thought
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f to use when deciding to engage in experiments that were directed to the invention, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d at 764
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Both of these articulations amount to the same concept: whether the scientific community 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
would have thought to do something
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at the time of invention is very much dependent on 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
what activities scientists had already been engaged in at the time.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Of course, the inverse concept also is true: if inventors engage in activities that run 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
counter
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to scientific thought, those activities can hardly be considered conventional under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This latter concept would similarly apply when a patent involves a combination of elements that the scientific community would not have thought to use or implement to deliver a new, improved and useful result. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS100&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 100
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe term \u8216\'3fprocess\rquote  means process, art or method, and includes a new use of a known process.\u8221\'3f). Indeed, the new and useful result of a combination patent resides precisely in a combination that neither existed in the prior art, nor was the possibility of such a combination well known in the art at the time of the invention.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When invention is based on the combination of elements that cuts against the grain of scientific thought, this heightens the novelty of invention itself.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B017172035479688_ID0EECCK_31}{\*\bkmkend co_fnRef_B017172035479688_ID0EECCK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B017172035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
17
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This is not to say that all inventions must cut against the grain to supply inventiveness. Far from 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_908_31}{\*\bkmkend co_pp_sp_7903_908_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*908
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 it. This was not taught in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 nor was it in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
California Institute of Technology
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case. The common thread in both those cases was that both inventions were directed towards a specific problem in the art and improved functionality. By doing so, both patents contributed to the art. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034719813&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_1000&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1000" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g., Cal. Inst. of Tech.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 59 F.Supp.3d at 1000, 2014 WL 5661290, at *20
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCaltech\rquote s patents improve a computer\rquote s functionality by applying concepts unique to computing (like using a linear transform operation to encode data) to solve a problem unique to computing (data corruption due to noise).\u8221\'3f). Solving those problems was not said to preempt because the elements in each invention were combination patents and created new and useful results that did not foreclose the use of other means to arrive at that same result: \u8220\'3fit at least must be true that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 protects a unique computing solution that addresses a unique computing problem.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034719813&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_1000&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1000" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cal. Inst. of Tech.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 59 F.Supp.3d at 1000, 2014 WL 5661290, at *20
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102035479688_31}{\*\bkmkend co_anchor_B102035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 While not expressly referenced in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework, an underlying concern is general preemption. That concern was underscored in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As previously discussed, what lies at the core of preemption is the question of whether the patent \u8220\'3fforecloses more future invention than the underlying discovery could reasonably justify.\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B018182035479688_ID0EJOCK_31}{\*\bkmkend co_fnRef_B018182035479688_ID0EJOCK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B018182035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
18
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For example, a well-tailored invention seeking to solve a specific problem with specific claim limitations should not typically trigger preemption concerns, at least where the invention is new and useful.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B019192035479688_ID0EAPCK_31}{\*\bkmkend co_fnRef_B019192035479688_ID0EAPCK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B019192035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
19
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To satisfy the framework laid out in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therefore, the invention must \u8220\'3fsupply a \u8220\'3f \u8216\'3fnew and useful\u8217\'3f \u8221\'3f application of the idea in order to be patent eligible.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2357" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2357
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1852194692&pubNum=0000780&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_780_159&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_159" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Le Roy v. Tatham,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 55 U.S. 156, 159, 14 How. 156, 14 L.Ed. 367 (1852)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThere can be no doubt that, if this combination is new, and produces a new and useful result, it is the proper subject of a patent. The result is a new manufacture. And even if the mere combination of machinery in the abstract is not new, still, if used and applied in connection with the practical development of a principle, newly discovered, producing a new and useful result, the subject is patentable.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a48b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a48b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
2. Analysis of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In what amounts to a conspiracy of silence, while Millennium challenges both the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
and
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, both parties focus their 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis narrowly on the more tailored \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, likely because Millennium must prevail in its challenge with respect to both and plaintiffs are happy to argue 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 using the stronger of its two patents. Because 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_909_31}{\*\bkmkend co_pp_sp_7903_909_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*909
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid for lack of enablement, the analysis here will also focus on the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, although the likely implications for a similar analysis with respect to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 may at times be obvious.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B020202035479688_ID0EH1CK_31}{\*\bkmkend co_fnRef_B020202035479688_ID0EH1CK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B020202035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
20
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For the reasons set forth below, the court ultimately concludes that the claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are patent eligible, while finding the broader claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 foreclose more future inventions than the inventors narrow discovery could reasonably justify.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a58b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a58b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
a. Step One of the 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Framework
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112035479688_31}{\*\bkmkend co_anchor_B112035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 At step one, the court determines \u8220\'3fwhether the claims at issue are directed to ineligible subject matter.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Millennium argues that the claims as a whole are directed to an abstract idea, but places particular emphasis on element (b) and element (f) of claim 1 and the related claims. The latter recites a comparison \u8220\'3fof a person\rquote s metabolite/creatinine ratio to \u8216\'3fknown normative data\u8217\'3f (a population of metabolite/creatinine ratios).\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 63\u8211\'3f64.) Ameritox counters by pitching the invention at a more specific level, arguing that the claims are directed \u8220\'3fto quantifying a metabolite concentration by adjusting the concentration for the patient\rquote s hydration status and then statistically comparing the adjusted concentration to a set of known normative data.\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B021212035479688_ID0EYKDK_31}{\*\bkmkend co_fnRef_B021212035479688_ID0EYKDK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B021212035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
21
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 87.) 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_910_31}{\*\bkmkend co_pp_sp_7903_910_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*910
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This, Ameritox argues, reflects the purpose of the invention\u8212\'3fproviding a method to improve medication monitoring and identifying aberrant drug use.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court finds Millennium\rquote s position more persuasive. While the skilled addressee would view comparative analysis of the invention as one that seeks to achieve a new and useful result over prior urine screening protocols, this new and useful result still rests upon an abstract idea, at least at some level. This finding is consistent with the recent 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
\u8211\'3f
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision, which also involved method claims. Specifically, the claims identified \u8220\'3fa law of nature ( [
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] the precise sequence of BRCA genes and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
comparisons
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of wild-type BRCA sequences with certain 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I777c6a64995711de9b8c850332338889&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
mutations of those genes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 found in the test subject) and applied conventional techniques\u8221\'3f to determine a patient\rquote s propensity to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1\u8211\'3f,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d at 761
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In finding in favor of the defendant, the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
\u8211\'3f
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 court held that the comparative analysis of the invention \u8220\'3frecite[d] abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_762&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_762" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 762
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because the present case involves a comparative analysis like that found in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium satisfies step one of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.; see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022394590&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bilski v. Kappos,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 561 U.S. 593, 611\u8211\'3f12, 130 S.Ct. 3218, 177 L.Ed.2d 792 (2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (characterizing abstract idea as \u8220\'3fthe concept of hedging\u8221\'3f where claim limitations described initiating transactions and identifying market participants); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2356&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2356" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2356
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (characterizing abstract concept as \u8220\'3fintermediated settlement\u8221\'3f despite claim elements reciting use of shadow credit records and debit records); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034265558&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1354" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
buySAFE Inc. v. Google, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 765 F.3d 1350, 1354\u8211\'3f55 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that \u8220\'3f[t]he claims are squarely about creating a contractual relationship\u8221\'3f despite presence of more specific claim limitations); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_715&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_715" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 772 F.3d at 715
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that \u8220\'3fthe concept embodied by the majority of the limitations describes only the abstract idea of showing an advertisement before delivering free content\u8221\'3f despite presence of other limitations).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B022222035479688_ID0EPSDK_31}{\*\bkmkend co_fnRef_B022222035479688_ID0EPSDK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B022222035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
22
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
But as Millennium must readily acknowledge and as previously discussed, it would be a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rare
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case where a patent is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 directed to ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1293
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A]ll inventions, at some level ... apply laws of nature, natural phenomena or abstract ideas.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034297346&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AutoForm Eng\rquote g GMBH v. Eng\rquote g Tech. Assocs., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. 10\u8211\'3f14141, 2014 WL 4385855, at *3\u8211\'3f4 (E.D.Mich. Sept. 5, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034981694&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ameranth, Inc. v. Genesis Gaming Solutions, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. 11\u8211\'3f00189, 2014 WL 7012391, at *6 (C.D.Cal. Nov. 12, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that the cotton gin could 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_911_31}{\*\bkmkend co_pp_sp_7903_911_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*911
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 sound abstract if one uses broad enough terms); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Michael V. Risch, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0343014835&pubNum=0001250&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Everything is Patentable,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 75 
}
{\b0 \cf19 \f2 \i0 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tenn. L.Rev.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 591 (2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. No doubt, this is precisely why 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 has traditionally been considered a \u8220\'3fthreshold test\u8221\'3f under the statute. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 450 U.S. at 188, 101 S.Ct. 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fthat process is at the very least not barred at the threshold by 101\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030568953&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1348&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1348" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alexsam, Inc. v. IDT Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 715 F.3d 1336, 1348 (Fed.Cir.2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Mayer, J., dissenting) (\u8220\'3fWhether claims are directed to statutory subject matter is a \u8220\'3fthreshold\u8221\'3f question.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a68b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a68b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
b. Step Two of the 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Framework
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122035479688_31}{\*\bkmkend co_anchor_B122035479688_31}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132035479688_31}{\*\bkmkend co_anchor_B132035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Holding that the claims are directed to an abstract idea, however, does not win the day for Millennium. As noted at the outset, an invention is not rendered ineligible simply because it involves an abstract idea. Applications of concepts \u8220\'3fto a new and useful end\u8221\'3f remain eligible for patent protection. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Benson,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 409 U.S. at 67, 93 S.Ct. 253
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). To meet this second step under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims directed to an abstract idea must contain an \u8220\'3finventive concept,\u8221\'3f that is \u8220\'3fan 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
element or combination of
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method for quantifying at least one metabolite in a biological sample comprising the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(a) providing one biological sample obtained from a patient on a prescribed medication regimen, wherein the sample comprises at least one test metabolite, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb200 
urine;
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(b) providing one set of known normative data specific to a reference metabolite, wherein the set of data is collected from a population that is on a prescribed medication regimen;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(c) contacting the biological sample with an analytical device;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(d) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
detecting
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 the presence of at least one test metabolite in the biological sample with the device, wherein the device is capable of measuring the concentration of the test metabolite in the sample;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(e) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
normalizing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 the biological sample to adjust for changes in the patient\rquote s hydration status by determining the metabolite/creatinine ratio of the patient; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(f) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
quantifying
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 the concentration of at least one test metabolite in the biological sample by comparing a ratio between the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite concentration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8242\'3f680 patent at 21:9\u8211\'3f32.) For ease of reference, elements (a)-(d) will be described as the \u8220\'3fdetection\u8221\'3f steps. Element (e) will be described as the \u8220\'3fnormalization\u8221\'3f step. Element (f) will be described as the \u8220\'3fcomparative\u8221\'3f step.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Millennium argues that the claims are conventional because they \u8220\'3fdirect medical professionals to measure the level of a drug metabolite, to normalize data via a creatinine ratio, and then to compare that value against the creatinine ratios of a population of individuals.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 78.) Millennium further argues that because these elements are conventional, the invention lacks an \u8220\'3finventive concept\u8221\'3f beyond the abstract idea itself.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ameritox\rquote s position is more nuanced. Ameritox argues that the claim elements are unconventional because the asserted claims are drawn to specific methods of monitoring medication through normalization and quantification of metabolites in a urine sample. Ameritox contends that these steps contain an inventive concept because the process described seeks to implement a novel solution to a pre-existing problem in the field. (Pl.\rquote s Opp\rquote n (dkt. # 172) 99.) Indeed, much of Ameritox\rquote s 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_912_31}{\*\bkmkend co_pp_sp_7903_912_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*912
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 argument centers on the fact that: (1) the invention 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
produces
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 an improved result over existing technology; and (2) the necessary inventive concept is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
combining
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the normalization step with the detection and comparative steps. As to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the court agrees.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
First,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 when the invention is examined as an ordered combination, the combination of steps produces a new and useful result. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (the patent statute provides protection for \u8220\'3fany new and useful process\u8221\'3f). The instant case shares similarities with 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in this respect. In both cases, the subject patents are directed to abstract ideas that improve pre-existing technology. Specifically, like the rubber curing improvements taught in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent, new improvements are similarly taught in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (albeit with respect to drug compliance monitoring). Indeed, each additional step taught directs the skilled addressee to an invention that allows quantifiable analysis of urine samples to determine a patient\rquote s compliance with a prescribed drug regimen. This type of improvement in existing technology is the type of invention that the statute seeks to encourage, not dismiss. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
450 U.S. at 183, 101 S.Ct. 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2359&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2359" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2359
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (looking at improvements in the \u8220\'3ffunctioning\u8221\'3f of a computer and the \u8220\'3ftechnical field\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022394590&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bilski,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 561 U.S. at 601, 130 S.Ct. 3218
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCongress took this permissive approach to patent eligibility to ensure that ingenuity should receive a liberal encouragement.\u8221\'3f) (internal quotation marks omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Judge Chen similarly upheld under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 scrutiny, an invention that addressed the challenge of retaining website visitors that was specific to the internet, as opposed to the \u8220\'3fperformance of a business practice known prior to the \u8216\'3fpre-internet world.\u8217\'3f 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1257&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1257" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d at 1257
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although the patent claimed a solution \u8220\'3frooted in computer technology,\u8221\'3f Judge Chen found the hybrid functionality of the invention constituted inventive concept. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This holding was reinforced by the fact that the claims addressed the problem of retaining website visitors otherwise instantly transported away from a website after \u8220\'3fclicking\u8221\'3f on an advertisement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 While the invention at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was in the software field, that decision establishes that inventive concept can be established by something more than \u8220\'3fconventional functioning\u8221\'3f that targets and improves existing technological processes for a specific problem in field of the invention. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.; see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035322819&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wavetronix LLC v. Iteris, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. A\u8211\'3f14\u8211\'3fCA\u8211\'3f970\u8211\'3fSS, 2015 WL 300726, at *6 (W.D.Tex. Jan. 22, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2358&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2358" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2358
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, the \u8242\'3f680 specification states that previous urine protocols were restricted in their application because they could only test for positive or negative results as to the \u8220\'3fpresence or absence of a drug metabolite in urine.\u8221\'3f (\u8242\'3f680 patent at 2:64\u8211\'3f67.) This problem was described as a \u8220\'3fmajor difficulty\u8221\'3f in the art because of the \u8220\'3flarge amount of variance in urine drug concentrations, mostly due to variations in hydration and urinary output volume.\u8221\'3f (\u8242\'3f680 patent at 1:51\u8211\'3f52.) In addressing the problem, the inventors coupled the normalization step with the comparative step, allowing for more accurate assessment of aberrant drug use. Nothing in Millennium\rquote s summary judgment materials rebuts what was plainly identified on the face of the specification as a problem in the field, nor directly rebuts the solution that the patent provided. This is telling.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B023232035479688_ID0ERNEK_31}{\*\bkmkend co_fnRef_B023232035479688_ID0ERNEK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B023232035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
23
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Just as 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_913_31}{\*\bkmkend co_pp_sp_7903_913_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*913
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the patent in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was deemed eligible because it solved a \u8220\'3fproblem specifically arising in the realm of computer networks,\u8221\'3f so, too, does the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 solve a unique problem with respect to drug testing technology. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1257&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1257" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d at 1257
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034719813&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_1000&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1000" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cal. Inst. of Tech.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 59 F.Supp.3d at 1000, 2014 WL 5661290, at *20
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 protects a unique computing solution that addresses a unique computing problem\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2359&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2359" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2359
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe method claims do not ... purport to improve the functioning of the computer itself.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Second,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium\rquote s analysis of the second 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is flawed. As an initial matter, Millennium argues that the comparative step must be filtered out of the analysis when looking at a combination patent, because it is either a \u8220\'3fknown method\u8221\'3f or \u8220\'3fan unpatentable ... process.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 78.) But there is nothing in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 suggesting that any steps are \u8220\'3ffiltered out\u8221\'3f when considering a combination patent. To the contrary, the invention in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was considered as \u8220\'3fa whole\u8221\'3f when assessing the second step of the framework. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2359&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2359" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
134 S.Ct. at 2359
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fConsidered as an ordered combination [and] ... [v]iewed as 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
a whole,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 petitioner\rquote s method claims simply recite the concept of intermediated settlement as performed by a generic computer.\u8221\'3f (internal quotations omitted, emphasis added)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alternatively, Millennium argues that instead of ignoring the comparative step, the detection and normalization steps must be discounted because they exist in the prior art, leaving only an abstract idea at the comparative step. (Def.\rquote s Opening Br. (dkt. # 130) 78.) Essentially, Millennium appears to assert that any additional steps beyond the abstract idea do not elevate the claim to \u8220\'3finventive concept,\u8221\'3f because each step was either \u8220\'3festablished\u8221\'3f or \u8220\'3fconventional.\u8221\'3f 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) Not so under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Specifically, looking at the normalization step, Millennium merely relies on its proposed finding that: \u8220\'3fNormalizing urine samples [had] been routine and conventional practice for over 40 years.\u8221\'3f (Dr. Alan H. Wu Invalidity Report (\u8220\'3fWu Invalidity Rept.\u8221\'3f) (dkt. # 115) \u182\'3f 112.) To support this proposed finding, Millennium infers that because creatinine normalization was mentioned in the George article, someone skilled in the art would know to simply combine the normalization step with the detection and comparative steps. Millennium argues that this finding is also supported by Dr. Wu, who opined that for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 purposes, \u8220\'3fneither the individual claim steps of the patented methods nor the series of claim steps in the patented methods are novel.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In reviewing the experts\rquote  reports, however, there is nothing that supports a finding that the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
combination
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the steps is routine and conventional.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B024242035479688_ID0E51EK_31}{\*\bkmkend co_fnRef_B024242035479688_ID0E51EK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B024242035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
24
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For example, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_914_31}{\*\bkmkend co_pp_sp_7903_914_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*914
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dr. Wu merely isolates the prior art in disparate references, but provides no meaningful rationale for why they would be combined. Even more telling, Wu cherry-picks aspects of the George article while wholly ignoring those sections that steer away from the combination claimed in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When looking at a combination patent, what courts most want to know is: who would have thought to combine the known elements in the first place and why?
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B025252035479688_ID0E63EK_31}{\*\bkmkend co_fnRef_B025252035479688_ID0E63EK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B025252035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
25
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Providing such evidence is even more important for a moving party in the summary judgment context, where all \u8220\'3freasonable inferences\u8221\'3f are made in the light most favorable to \u8220\'3fthe nonmoving party.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032671306&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_761&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_761" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Helman v. Duhaime,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 742 F.3d 760, 761 (7th Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. When, as here, Millennium is asking the court to infer that the combination of elements is conventional, it must supply 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
some
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 evidence to convince the trier of fact to accept its version of events. Since those facts are lacking here, Millennium\rquote s position is necessarily rejected. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999104074&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_504&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_504" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Schacht,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 175 F.3d at 504
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that summary judgment is \u8220\'3fnot a dress rehearsal or practice run,\u8221\'3f but the \u8220\'3fput up or shut up moment\u8221\'3f in which a party must show what evidence it has to convince a trier of fact to accept its version of events). In the end, Millennium does not approach its burden of producing \u8220\'3fclear and convincing\u8221\'3f evidence that the combination taught in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was known.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Third,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and a close corollary of the second, evidence of combination helps to guard against hindsight bias. To ignore this concern would provide a \u8216\'3fblank check\u8217\'3f to all those who challenge patents without sufficient legal or evidentiary basis. Given that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 now expressly requires that courts look at patented elements in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
combination
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 when assessing inventive concept (as did 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ), the concern of hindsight bias has as much relevance to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge as it does a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See generally 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1299&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1299" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1299
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fat least the combination of those steps, were in context obvious, already in use, or purely conventional\u8221\'3f). Where, as here, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is effectively being used as a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
de facto
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge, some 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
rational basis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for combination must be proffered, particularly in a case like this where the patent has survived prosecution and two further rounds of re-examination, as plaintiffs point out (repeatedly) in briefing. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012126122&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
KSR Int\rquote l Co. v. Teleflex Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 550 U.S. 398, 417\u8211\'3f18, 127 S.Ct. 1727, 167 L.Ed.2d 705 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting the need to \u8220\'3fbe cautious of arguments reliant upon ex post reasoning\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034312772&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Scientific Plastic Prods., Inc. v. Biotage AB,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 766 F.3d 1355, 1362\u8211\'3f63 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Moore, J., dissenting); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1983151589&pubNum=0000350&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_350_1553&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1553" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
W.L. Gore & Assocs., Inc. v. Garlock, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 721 F.2d 1540, 1553 (Fed.Cir.1983)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fTo imbue one of ordinary skill in the art with knowledge of the invention in suit, when no prior art reference or references of record convey or suggest that knowledge, is to fall victim to the insidious effect of a hindsight syndrome wherein that which only the inventor taught is used against its teacher.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Finally,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 having had the benefit of claims construction and viewing the claims through the lens of the skilled addressee, the court is well versed in the state of the art at the time of the invention. In many 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_915_31}{\*\bkmkend co_pp_sp_7903_915_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*915
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ways, claim construction has confirmed the basic subject matter of the invention. There would seem no reason why the state of the art should not also be used to analyze claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 context when evaluating the \u8220\'3fsignificance of the additional steps\u8221\'3f for the purposes of assessing inventive concept. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1304&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1304" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1304
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Like other provisions of the statute, it is the state of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
art
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that provides the objective baseline for the analysis. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 should be no exception. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.; 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2129&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2129" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nautilus, Inc. v. Biosig Instruments, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2120, 2129, 189 L.Ed.2d 37 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A] patent\rquote s claims, viewed in light of the specification and prosecution history, [need only] inform those skilled in the art about the scope of the invention with reasonable certainty.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1966112593&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Graham v. John Deere Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 383 U.S. 1, 17\u8211\'3f18, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (skilled addressee in the obviousness context); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004844816&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1116" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 381 F.3d 1111, 1116 (Fed.Cir.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (using prior art as an \u8220\'3fobjective baseline\u8221\'3f from which in claims construction); Lemley, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
supra
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 note 20, at 1330.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, Millennium can point to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
no
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reference demonstrating the existence of or even suggesting the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
combination
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the comparative step with the additional steps of the invention. And there is certainly nothing in the art that demonstrates that such a combination was well-known. This provides indicia that the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is inventive for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 purposes. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1297\u8211\'3f99
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Indeed, in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Justice Breyer explained that the invention in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was patentable because the \u8220\'3fordered combination\u8221\'3f of the steps of the claimed invention were \u8220\'3fnowhere suggested\u8221\'3f to be \u8220\'3fin context obvious, already in use, or purely conventional.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1299&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1299" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1299
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030892653&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Oleksy v. Gen. Elec. Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. 06\u8211\'3fC\u8211\'3f01245, 2013 WL 3233259, at *5 (N.D.Ill. June 26, 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fOleksy\rquote s process is patentable despite its reliance on mathematical equation because of the way the equation is integrated into a process that also uses steps that are not obvious, already in use or purely conventional\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033168690&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_1093&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1093" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
France Telecom S.A. v. Marvel Semiconductor Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 39 F.Supp.3d 1080, 1093, 2014 WL 1478850, at *8\u8211\'3f9 (N.D.Cal.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding the claims are \u8220\'3fnarrow and they confine and tie down the otherwise abstract processes cited\u8221\'3f and provide \u8220\'3f \u8216\'3finventive concepts\rquote  that exceed the prior art, namely coding in parallel and a novel method of iterative coding\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, Millennium has failed to offer any evidence that someone in the scientific community would have even \u8220\'3fthought\u8221\'3f to combine the claimed elements. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d at 764
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 purposes, this makes the claims new and useful over the prior art. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.; see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 450 U.S. at 188, 101 S.Ct. 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A] new combination of steps in a process may be patentable even though all the constituents of the combination were well known and in common use before the combination was made.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_715&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_715" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 772 F.3d at 715
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A]ny 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
novelty
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in implementation of the idea is a factor to be considered only in the second step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis.\u8221\'3f (emphasis added)); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1880199725&pubNum=0000780&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_780_102&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_102" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Parks v. Booth,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 102 U.S. 96, 102, 26 L.Ed. 54 (1880)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As stated previously, the George Article is indicative of routine and well-known techniques at the time of the invention in the urine testing world. Not only was it frequently cited in the prosecution history, but both parties\rquote  experts rely upon the article for purposes of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
102
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
and
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium expressly put the article into evidence to support its position on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The article also predated the invention by four years, making it indisputably well known before the patent\rquote s filing date. The purpose of the study as described in the George Article was to find a noninvasive way of testing for drug compliance.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_916_31}{\*\bkmkend co_pp_sp_7903_916_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*916
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 At the end of the study, the article expressly concluded that creatinine normalization was problematic and \u8220\'3f[f]or practical purposes ... the only reliable method available to monitor 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 compliance is the use of plasma 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1f2a6f475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
methadone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 drug testing.\u8221\'3f (Mandel Decl., Ex. 43 (dkt. # 129\u8211\'3f43) 85.) Indeed, the George Article not only indicates that use of creatinine normalization was anything but routine and commonplace in the urine drug testing protocols, but suggests that it was viewed as 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
unreliable.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012204048&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1161&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1161" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Leapfrog Enters., Inc. v. Fisher\u8211\'3fPrice, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 485 F.3d 1157, 1161 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fApplying modern electronics to older mechanical devices has been commonplace in recent years.\u8221\'3f). Instead, blood testing at the time of the invention was considered the only reliable method to determine whether a patient was complying with a prescribed drug regimen.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B026262035479688_ID0EMYFK_31}{\*\bkmkend co_fnRef_B026262035479688_ID0EMYFK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B026262035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
26
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
If the seminal reference in the art at the time stated that blood sampling was by far preferable to urine normalization, because of the latter\rquote s unreliability, why would anyone in the industry have thought to use a normalization step for urine in drug protocols? 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d at 764
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (addressing what a \u8220\'3fscientist would have thought of\u8221\'3f with respect to gene sequences). Regardless, a normalization step that others skilled in the art had rejected as unreliable can hardly be considered conventional in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 context.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B027272035479688_ID0EC3FK_31}{\*\bkmkend co_fnRef_B027272035479688_ID0EC3FK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B027272035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
27
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Moreover, it is this normalization step that distinguishes the present patent\rquote s claims from the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent claims. The fact that the claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are even more specific\u8212\'3flimiting their reach to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
creatinine
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 normalization\u8212\'3ffurther narrows their scope, especially since there were 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
other
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 means to adjust for changes in a patient\rquote s hydration status.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B028282035479688_ID0EC4FK_31}{\*\bkmkend co_fnRef_B028282035479688_ID0EC4FK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B028282035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
28
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because the inventors cut against scientific thought at the time of the invention, and because the invention targeted a specific problem in the field of urine testing, the court finds that there is sufficient inventive concept in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the purposes of meeting the threshold test of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_764&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_764" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BRCA1\u8211\'3f,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 774 F.3d at 764
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_715&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_715" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 772 F.3d at 715
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
each
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the reasons above address Millennium\rquote s 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge in isolation, Millennium also fails to proffer any meaningful evidence to support a finding of preemption for the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034389958&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Helios Software, LLC v. SpectorSoft Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 No. 12\u8211\'3f081\u8211\'3fLPS, 2014 WL 4796111, at *17 (D.Del. Sept. 18, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that because defendant \u8220\'3fprovided no support\u8221\'3f the court could not find \u8220\'3fthat the patents-in-suit were drawn to [eligible subject matter]\u8221\'3f). This further suggests that the limitations in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 do not have preemptive effect, something reinforced by 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_917_31}{\*\bkmkend co_pp_sp_7903_917_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*917
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dr. Orsulak, who noted several other methods besides blood sampling that the patent also did not preempt. These examples were not controverted by Millennium\rquote s expert witnesses or in its briefing. (Def.\rquote s Reply (dkt. # 183) 56\u8211\'3f58.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142035479688_31}{\*\bkmkend co_anchor_B142035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 None of this can be said with respect to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On the contrary, the sweeping claim to \u8220\'3fa method for quantifying at least one metabolite in at least one biological sample\u8221\'3f refers to nothing more than the claimed discovery of a method for \u8220\'3fquantifying the concentration of at least one test metabolite in the biological sample\u8221\'3f against an 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
unspecified and undisclosed
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fknown normative data specific to the reference metabolic concentration.\u8221\'3f Unlike element (e) of the claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, there is no teaching against the art well-known at the time with respect to the use of creatinine concentration in urine, no specification of a similar test metabolite in other biological samples, or unique relationships between at least one biological sample obtained from a patient and a set of known normative data specific to the referenced metabolite concentration. In short, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 merely deletes the limitation of the biological sample of urine leaving a sweeping claim to biological samples consisting of \u8220\'3fblood, saliva, sweat, spinal and brain fluids.\u8221\'3f (\u8242\'3f895 patent at 4:58\u8211\'3f60.) Not only does the patent not provide enablement for biological samples other than urine under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for reasons discussed below, but it amounts to nothing more than speculative claims that purport to preempt similar discoveries with respect to other biological samples. This would appear exactly the kind of preemption strongly disfavored by the United States Supreme Court because it \u8220\'3fforecloses more future invention than the underlying discovery could reasonably justify.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Lemley, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
supra
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 note 20, at 1329\u8211\'3f30 (\u8220\'3fThe abstract ideas exception should disallow those claims to ideas unmoored to real-world applications, taking into account the extent to which the claim forecloses after-arising embodiment of the idea, the nature and extent of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
prior art,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the level of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
disclosure
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by the inventor.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Indeed, as detailed already, it is the very combination of integers in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that supplies the inventive concept to that invention. By stark contrast, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 makes one of those elements redundant\u8212\'3fnamely element (e)\u8212\'3feffectively seeking to broaden that patent because there is one less limitation that must be met when seeking infringement with respect to, for 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 blood. Said another way, and to draw an analogy with a mechanical patent, element (e) provides a pivot point between the detection steps ((a)-(d)) and the comparative step (f) that is essential to invention described in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rendering that pivot point irrelevant to the combination of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3ffor example, because blood does not require creatinine-normalization\u8212\'3fcuts away from the novelty and inventiveness of the patent itself, which in turn, cuts away from any justification for allowing the broad claim scope of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, without restriction to urine screening, the claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and for reasons that are foreshadowed here, invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a78b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a78b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a78b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a78b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 112
}}}
\sb200 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 and Other Invalidity Challenges
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Regardless of the court\rquote s conclusions on claim construction and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Millennium argues that the patents-in-suit are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Specifically, Millennium argues that the claims of both patents are invalid under the doctrines of indefiniteness and enablement.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Since both patents share the same specification, the court addressed the patents together, just as Millennium did in briefing.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a88b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a88b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_918_31}{\*\bkmkend co_pp_sp_7903_918_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*918
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
1. Indefiniteness
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152035479688_31}{\*\bkmkend co_anchor_B152035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Because the court has earlier found that the claims 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
can
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 be construed by a person having ordinary skill in the art, much of Millennium\rquote s indefiniteness argument falls flat, but the court will briefly address why, beginning with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 itself. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Paragraph 2 of \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides that a patent\rquote s specification must \u8220\'3fconclude with one or more claims particularly pointing out and distinctly claiming the subject matter [that] the applicant regards as [the] invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u182\'3f\u182\'3f 2. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nautilus, Inc. v. Biosig Instruments, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2120, 189 L.Ed.2d 37 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court recently explained that under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u182\'3f\u182\'3f 2, \u8220\'3fa patent\rquote s claims, viewed in light of the specification and prosecution history, [need only] inform those skilled in the art about the scope of the invention with 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reasonable certainty.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2129&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2129" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2129
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). The Supreme Court further explained in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nautilus
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that indefiniteness requires a \u8220\'3fdelicate\u8221\'3f balance:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
On the one hand, the definiteness requirement must take into account the inherent limitations of language. Some modicum of uncertainty ... is the price of ensuring the appropriate incentives for innovation.... At the same time, a patent must be precise enough to afford clear notice of what is claimed.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2128&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2128" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2128\u8211\'3f29
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal citations and quotation marks omitted). Accordingly, the definiteness requirement \u8220\'3fmandates clarity,\u8221\'3f while recognizing that absolute precision is \u8220\'3funattainable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2129&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2129" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2129
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, Millennium primarily challenges the validity of Ameritox\rquote s construction of a term in element (f) of each of the independent claims in the patents-in-suit\u8212\'3f\u8220\'3fquantifying the concentration.\u8221\'3f Millennium argues that under this now adopted construction, the independent claims are all rendered indefinite. Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 2, however, Millennium must provide clear and convincing evidence that the claims fail to provide reasonable certainty as to the scope of the patent. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2242&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2242" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Microsoft Corp. v. i4i Ltd. P\rquote ship,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 131 S.Ct. 2238, 2242, 180 L.Ed.2d 131 (2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. That threshold has not been satisfied here, particularly in light of what is stated in the specification and the prosecution history.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With respect to the former, Example 1 provides a detailed summary of the invention, which is cross-referenced to Figure 4. The example explains how the claimed invention will \u8220\'3fimprove the ability of clinicians to predict appropriate use of prescribed medication\u8221\'3f and \u8220\'3fdetect and quantify inappropriate use.\u8221\'3f (\u8242\'3f680 patent at 6:58\u8211\'3f62.) The inventors further teach how this is achieved with respect to element (f) via statistical analysis of normative data establishing \u8220\'3f95% prediction intervals\u8221\'3f to identify aberrant medication. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 6:30\u8211\'3f
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.) That data, as the specification suggests, can then be translated into prediction limits, which are depicted in Figure 4 of the patent:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a98b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a98b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860a98b1011ea80afece799150}{\*\bkmkend co_anchor_I109860a98b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_919_31}{\*\bkmkend co_pp_sp_7903_919_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
*919
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860aa8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860aa8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/Blob/I00eb58a0bd0411e48e84010000000000.png?originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentImage&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw612 \pich360 \picwgoal4640 \pichgoal2729 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}}}}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/Blob/I00eb58a0bd0411e48e84010000000000.png?originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentImage&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8203\'3f
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8242\'3f680 patent at FIG. 4.) The circles represent normative data. The black squares reflect \u8220\'3fknown outliers\u8221\'3f or \u8220\'3faberrant results.\u8221\'3f The graph demonstrates that quantifying a urine sample quickly identifies instances of nonadherence. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4:6\u8211\'3f10; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 11:1112 (\u8220\'3fThe data used in this study was sufficient to yield a highly significant regression analysis that allowed the demonstration of known outliers.\u8221\'3f).)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Examples 2, 5, 6, 7, 8, 12, and the \u8220\'3fSummary of the Invention,\u8221\'3f likewise describe ranges, confidence intervals, and regression equations, established from normative data to compare patient information and to \u8220\'3fidentify aberrant drug use patterns.\u8221\'3f 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3:2028, 45\u8211\'3f54; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at Exs. 2, 5, 6, 7, 8, 12.) These examples provide objective data that the skilled addressee could rely upon to determine the scope of the patented claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Compare 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1259&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1259" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DDR,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d at 1259\u8211\'3f60
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that the term \u8220\'3flook and feel\u8221\'3f satisfied 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because it \u8220\'3fhad an established, sufficiently objective meaning in the art\u8221\'3f), 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
and 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033624856&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1340&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1340" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Augme Techs., Inc. v. Yahoo! Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 755 F.3d 1326, 1340 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that the term \u8220\'3freceiving, by an ingest server, the unique identifier to the digital content\u8221\'3f satisfied 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because it was \u8220\'3fclear on its face\u8221\'3f), 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
with 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034312812&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1370&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1370" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Interval Licensing LLC v. AOL, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 766 F.3d 1364, 1370\u8211\'3f71 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that the term \u8220\'3funobtrusive manner\u8221\'3f was indefinite under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because it was \u8220\'3fhighly subjective,\u8221\'3f \u8220\'3fprovide[d] little guidance to one of skill in the art,\u8221\'3f and \u8220\'3foffer[ed] no objective indication of the manner in which content images are to be displayed to the user\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, when the skilled addressee views the prosecution history, she would readily appreciate the inventors\rquote  explanation that element (f) \u8220\'3fallows statistical analysis of the drug metabolite level in the urine to determine if the medication is utilized in a manner consistent with the prescription or that the potential dose may have been.\u8221\'3f (Mandel Decl., Ex. 24 (dkt. # 129\u8211\'3f24) pp. 14\u8211\'3f15; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ex. 17 (dkt. # 129\u8211\'3f17) p. 9.) The use of well-known statistical models in the prosecution history is consistent with the teachings in the specification itself\u8212\'3fand, when read together, this would confirm to the skilled addressee with reasonable certainty both how the patented invention works and the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_920_31}{\*\bkmkend co_pp_sp_7903_920_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*920
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fscope of the invention\u8221\'3f itself. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2129&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2129" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nautilus,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2129
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B162035479688_31}{\*\bkmkend co_anchor_B162035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium raises two more arguments that at least deserve mention. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
First,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium emphasizes the term \u8220\'3fquantifying the concentration\u8221\'3f is not \u8220\'3fexpressly defined anywhere in the specification or prosecution history of the patents-in-suit.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 30.) However, whether the inventors \u8220\'3fexpressly defined\u8221\'3f a claim term is not the test for indefiniteness. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004170135&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bancorp Serv., L.L.C. v. Hartford Life Ins. Co.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 359 F.3d 1367, 1373 (Fed.Cir.2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe failure to define the term is, of course, not fatal, for if the meaning of the term is fairly inferable from the patent, an express definition is not necessary.\u8221\'3f). At some level, ambiguity resides in the claims of most (if not all) patented inventions, but as the Supreme Court explained in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nautilus,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3f[s]ome modicum of uncertainty is the price of ensuring the appropriate incentives for innovation.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496707&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2128&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2128" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
134 S.Ct. at 2128\u8211\'3f29
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Second,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium argues that the claims are indefinite because one of the inventors, Dr. Larson, misunderstood what was meant by the \u8220\'3fquantifying\u8221\'3f step at his deposition. While Millennium placed heavy emphasis on this point, the Federal Circuit has long recognized that an inventor, represented by counsel during the application process, may not understand the meaning of a precise claim in a patent as issued.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[C]ommonly the claims are drafted by the inventor\rquote s patent solicitor and they may even be drafted by the patent examiner in an examiner\rquote s amendment (subject to the approval of the inventor\rquote s solicitor). While presumably the inventor has approved any changes to the claim scope that have occurred via amendment during the prosecution process, it is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not unusual for there to be a significant difference between what an inventor thinks his patented invention is and what the ultimate scope of the claims
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 is after allowance by the PTO.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995081690&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_985&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_985" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Markman v. Westview Instruments, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 52 F.3d 967, 985\u8211\'3f86 (Fed.Cir.1995)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000390748&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Solomon v. Kimberly\u8211\'3fClark Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 216 F.3d 1372, 1380 (Fed.Cir.2000)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034660405&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Componex Corp. v. Electronics For Imaging, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2014 WL 5361946, at *8 (W.D.Wis. Oct. 21, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In light of the above, both the specification and the prosecution history supply enough notice so that the skilled addressee would understand the scope of the claims with reasonable certainty.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B029292035479688_ID0E2DHK_31}{\*\bkmkend co_fnRef_B029292035479688_ID0E2DHK_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B029292035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
29
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As such, the court finds that the claims meet the requirements of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u182\'3f\u182\'3f 2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860ac8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860ac8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
2. Enablement
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The enablement requirement provides that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The specification shall [describe] the manner and process of making and using [the invention], in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_921_31}{\*\bkmkend co_pp_sp_7903_921_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*921
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 pertains, or with which it is most nearly connected, to make and use the [invention].
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B172035479688_31}{\*\bkmkend co_anchor_B172035479688_31}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B182035479688_31}{\*\bkmkend co_anchor_B182035479688_31}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B192035479688_31}{\*\bkmkend co_anchor_B192035479688_31}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B202035479688_31}{\*\bkmkend co_anchor_B202035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 To be enabling, \u8220\'3fthe specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without \u8216\'3fundue experimentation.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028399326&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MagSil Corp. v. Hitachi Global Storage Techs., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 687 F.3d 1377, 1380\u8211\'3f81 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). \u8220\'3fThe enablement determination proceeds as of the effective filing date of the patent.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citation omitted). \u8220\'3fEnablement serves the dual function in the patent system of ensuring adequate disclosure of the claimed invention and of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
preventing claims broader than the disclosed invention.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citation omitted, emphasis added). A court may consider the following factors when determining if a disclosure requires undue experimentation: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021835410&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_940&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_940" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ALZA Corp. v. Andrx Pharms., LLC,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 603 F.3d 935, 940 (Fed.Cir.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Millennium addresses enablement at two levels. On one level, Millennium argues that had the court adopted its proposed construction of element (f), then the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
both
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patents are invalid for lack of enablement. Even accepting the court\rquote s construction, on another level, Millennium argues that the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is still invalid due to its failure to teach the claimed methods directed to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
non-urine
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 biological samples. Since the court did 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 adopt Millennium\rquote s construction, the first argument obviously falls away, but the second of these arguments is persuasive.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B212035479688_31}{\*\bkmkend co_anchor_B212035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As discussed earlier, one skilled in the art would readily appreciate that the claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are not limited to urine samples, which contrasts starkly with similar claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Unlike that patent, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims expressly extend to other biological samples, including \u8220\'3fblood, saliva, sweat, and spinal and brain fluids, or a combination thereof.\u8221\'3f (\u8242\'3f895 patent at 4:58\u8211\'3f60.) Tellingly, Ameritox neither disputes this contrast, nor explains how the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 teaches the practice of the claimed invention as to any of these non-urine samples except in the broadest possible terms. The court finds this terminal to Ameritox\rquote s chances of succeeding with respect to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748793&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim Co. v. Medrad, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 481 F.3d 1371, 1378\u8211\'3f79 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that the patentee must provide a \u8220\'3freasonable enablement of the scope 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
of the range
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f of the patented embodiments (emphasis added)); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018942677&pubNum=0004637&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_4637_817&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_817" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gen. Elec. Co. v. SonoSite, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 641 F.Supp.2d 793, 817 (W.D.Wis.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that although a patentee need not describe \u8220\'3fhow to make and use every possible variant of the claimed invention,\u8221\'3f where claims are \u8220\'3fopen-ended,\u8221\'3f the patent would need to be supported by \u8220\'3freasonable enablement of the scope of the range\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In basic patent parlance, the teaching of how to practice the claimed invention supplies the \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
quid pro quo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the patent bargain.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748793&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 481 F.3d at 1380
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034981683&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1347&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1347" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Promega Corp. v. Life Technologies Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d 1338, 1347 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating that the \u8220\'3fscope of the claims\u8221\'3f must be \u8220\'3fcommensurate\u8221\'3f with the specification). In this respect, the \u8242\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not live up to its promise. The 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
only
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 biological sample in the specification is the same urine samples already disclosed and claimed in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Indeed, the bulk of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is primarily directed to explaining how creatinine normalization plays a critical role in 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_922_31}{\*\bkmkend co_pp_sp_7903_922_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*922
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 accounting for hydration when testing urine samples, not unlike the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This lack of disclosure as to the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
other
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 biological samples is enough to defeat the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on enablement grounds given that undue experimentation would obviously be required to determine how non-urine samples work in conjunction with creatinine normalization so to provide a new and useful result. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.; see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028399326&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MagSil,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 687 F.3d at 1380\u8211\'3f81
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fTo be enabling, the specification of a patent must teach ... without [the need] for undue experimentation.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reinforcing the strength of Millennium\rquote s argument is the fact that applying creatinine normalization to other biological samples (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 blood) makes no sense. As Millennium\rquote s unrebutted expert report explained, hydration does 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 need to be accounted for in non-urine, biological samples, since fluids, like blood, do not reflect variations in hydration like urine. (Wu Invalidity Rept. (dkt. # 115) \u182\'3f 100) (noting that, with respect to non-urine biological samples, \u8220\'3f[t]he body already has a defense mechanism in place to prevent wide variation in hydration and dehydration\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While the enablement inquiry also allows assessment of the state of the art and the relative skill of those scientists involved in the industry, the patent fares no better when considering these sources at the time of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 filing. On the contrary, the lack of teachings in the specification is not saved by what was known outside the specification\u8212\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 what was common general knowledge or commonplace. When turning to these sources, the skilled addressee would find references such as the George Article that make 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
no
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reference to how blood applies creatinine normalization to achieve more accurate results. Most likely, this is because, as Dr. Wu opines, it makes no difference since blood has built-in mechanisms to prevent wide variations in hydration. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not only is this not controverted in the parties\rquote  summary judgment materials, Ameritox goes so far as to say that the case is not about blood, it\rquote s about urine samples. Specifically, Ameritox concludes that because non-urine samples are not relevant to the other issues of this case\u8212\'3fin particular, infringement\u8212\'3fthe court should ignore Millennium\rquote s contention that the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid for lack of enablement. (Pl.\rquote s Opp\rquote n (dkt. # 172) 63\u8211\'3f64.) At the same time, Ameritox seems to be conceding that the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is irrelevant to the current lawsuit, it neither offers to withdraw the patent from these proceedings nor cite law as to how the much broader claims of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 satisfy an enablement inquiry.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Instead, Ameritox relies principally (really exclusively) on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032754692&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda Pharm. Co. Ltd. v. Zydus Pharm. USA, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 743 F.3d 1359 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, for the proposition \u8220\'3fthat the enablement requirement is met if the description enables any mode of making and using the invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032754692&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1369&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1369" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1369\u8211\'3f70
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotation omitted). More specifically, Ameritox contends that because Millennium does not dispute the \u8220\'3fclaims are ... enabled and operable with regards to urine ... [, t]hat is enough.\u8221\'3f (Pl.\rquote s Opp\rquote n (dkt. # 172) 105).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Just as Millennium\rquote s application lacked depth with respect to construction, Ameritox suffers from the same vice with respect to enablement on the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
First,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ameritox makes no effort to square what is said in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fregarding use of the word \u8220\'3fmode\u8221\'3f\u8212\'3fwith the well-established rule that the patent must teach how to practice the full scope of an invention. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030869489&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1384&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1384" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wyeth & Cordis Corp. v. Abbott Labs.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 720 F.3d 1380, 1384 (Fed.Cir.2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028399326&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MagSil Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 687 F.3d at 1380\u8211\'3f81
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (\u8220\'3fnot enabled when ... one of ordinarily skill in the art could not practice their full scope without undue experimentation\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029180449&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1309&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1309" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Edwards Lifesciences AG v. CoreValve, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_923_31}{\*\bkmkend co_pp_sp_7903_923_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*923
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 699 F.3d 1305, 1309 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe enablement defense does not require an intent to withhold; all that is required is a failure to teach how to practice the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
full scope
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the claimed invention.\u8221\'3f (emphasis added)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To use the language of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, if the putative mode does not provide means on how to make and use other embodiments of the invention, then it can hardly be considered a mode that allows the skilled addressee to \u8220\'3fpractice the full scope of the claimed invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029180449&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1309&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1309" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Edwards Lifesciences,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 699 F.3d at 1309
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This is precisely the case here: there is nothing in the evidence to show how the urine embodiment\u8212\'3fAmeritox\rquote s putative mode\u8212\'3fsupplies enough information to the skilled addressee to make and use the invention with respect to samples of blood, saliva, sweat, spinal and brain fluid. Accordingly, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid for lack of enablement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Second,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Ameritox\rquote s two sentence \u8220\'3fanalysis\u8221\'3f ignores that, as Millennium points out, the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case is factually inapposite to the present. In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the defendant argued that because the specification only disclosed one method of measuring the drug particles\rquote  diameter to determine whether the invention was infringed, the patent did not enable the claims for other methods of measuring drug particles. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032754692&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1369&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1369" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
743 F.3d at 1369
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3f[B]ecause the patent identifie[d] laser diffraction as a viable measurement technique, and there [was] no dispute that a skilled artisan would know how to use laser diffraction to measure particle diameter,\u8221\'3f the Federal Circuit found that the patent \u8220\'3fsufficiently 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
enabled the full scope
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the claims.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added). Thus, to satisfy the enablement requirement, the patentee was only required to show that there was at least one mode to determine how differing embodiments (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 different sizes of a drug particle) of the invention could infringe.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The present patent claims differ in kind from the patent claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in several respects. For instance, while the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 extends to the use of blood samples to quantify drug metabolites, it cannot be said that blood (or any of the other biological samples) are being used as a universal measuring device, as laser diffraction was in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case. In particular, laser diffraction was a mode for measuring whether an infringing embodiment fell within the full scope of the claims.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In contrast, here, each biological source represents an alternative embodiment of how the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 can be implemented. Urine is one embodiment, while blood is another entirely. Because blood is not taught in the specification, blood stretches the scope of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 beyond its description in the patent. Saliva, sweat, spinal and brain fluids are further embodiments that each expand the scope further. Moreover, each of these biological samples are embodiments of the invention unto themselves, expanding the scope of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 far beyond what is disclosed in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In expanding its scope dramatically, Ameritox was required to ensure that the disclosure was \u8220\'3fcommensurate\u8221\'3f with the specification. Its failure to provide the necessary 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
quid pro quo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 results in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 being held invalid. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034981683&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1347&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1347" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Promega Corp. v. Life Techs. Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 773 F.3d 1338, 1347 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999047064&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1195&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1195" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nat\rquote l Recovery Techs., Inc. v. Magnetic Separation Sys., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 166 F.3d 1190, 1195\u8211\'3f96 (Fed.Cir.1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[T]he public knowledge is enriched by the patent specification to a degree at least commensurate with the scope of the claims ... [being] less than or equal to the scope of enablement.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, there is nothing in the specification that teaches how creatinine-normalization can be combined with blood (much less other biological samples) to determine 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_924_31}{\*\bkmkend co_pp_sp_7903_924_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*924
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the scope of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028399326&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1381&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1381" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
MagSil Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 687 F.3d at 1381
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe specification must contain sufficient disclosure to enable an ordinarily skilled artisan to make and use the entire scope of the claimed invention at the time of filing.\u8221\'3f). As addressed earlier, the skilled addressee would also be of no assistance. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028399326&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1381&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1381" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1381
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Nor does Ameritox\rquote s briefing or affidavits even attempt to reconcile these obvious differences between 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the present case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A more apt case than 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748793&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim Co. v. Medrad, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 481 F.3d 1371 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On appeal in that case, the patentee unsuccessfully argued as Ameritox does here that the teaching of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
one
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 embodiment was enough for enablement purposes:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Liebel contends that the court erroneously considered whether an injector without a pressure jacket was enabled ... Because it is undisputed that Liebel provided an enabling disclosure of what it calls its preferred embodiment, viz., an injector with a pressure jacket, Liebel asserts that the court should have held that the disclosure was enabling for the full scope of the claims.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748793&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1378
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In construing the claims, however, the Federal Circuit concluded the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were \u8220\'3fnot limited to an injector with a pressure jacket.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748793&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. And, therefore, \u8220\'3fthe full scope of the claimed inventions include[d] injectors 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
with
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
without
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a pressure jacket.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As for the enablement question, and turning to the specification, the Federal Circuit then held that \u8220\'3fnowhere does the specification describe an injector with a disposable syringe without a pressure jacket.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1379. In fact, the Federal Circuit noted, \u8220\'3fthe specification teaches away from such an invention.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 When turning to the skilled addressee, the Federal Circuit found that \u8220\'3fundue experimentation\u8221\'3f would be required \u8220\'3fto make and use the injector without a pressure jacket.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1380. Because the specification did not teach how to make an embodiment of the invention\u8212\'3fan injector 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
without
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a pressure jacket\u8212\'3fand because the skilled artesian could not \u8220\'3ffill the gaps,\u8221\'3f the Federal Circuit held the \u8220\'3fclaims were invalid for lack of enablement.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Strong parallels exist between the present claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the claims in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B030302035479688_ID0E6SAM_31}{\*\bkmkend co_fnRef_B030302035479688_ID0E6SAM_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B030302035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
30
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Just as nowhere in the specification of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent did the patentee describe an injector without a pressure jacket, nowhere in the \u8242\'3f895 specification did the patentee describe embodiments of the invention based on blood, saliva, brain fluid or the other claimed biological samples. Moreover, and consistent with 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the skilled addressee in this case would be unable to \u8220\'3ffill the gaps\u8221\'3f in the specification so that invention could meet the enablement requirement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Because of the similarities between instant case and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 among others, the court has little hesitation in finding the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 invalid. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u182\'3f 1 (providing in pertinent part that the specification shall describe \u8220\'3fthe manner and process of making and using [the invention], in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the [invention]\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_925_31}{\*\bkmkend co_pp_sp_7903_925_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*925
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2014999898&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_999&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_999" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sitrick v. Dreamworks LLC,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 516 F.3d 993, 999\u8211\'3f1000 (Fed.Cir.2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming summary judgment that claims were invalid for lack of enablement when the claims encompassed both video games and movies, but the specification did not enable the invention for use in movies); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Auto. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013122378&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1285&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1285" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Techs. Int\rquote l, Inc. v. BMW of N. Am., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 501 F.3d 1274, 1285 (Fed.Cir.2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming summary judgment that the claims were invalid for lack of enablement when the specification did not enable one of the embodiments).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In sum, because of this fairly blatant overreach and because Millennium has demonstrated through clear and convincing evidence that the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 captures far more than what is taught in the specification, the court grants Millennium\rquote s motion for invalidity as to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 pursuant to \u167\'3f 112(a) of the statute. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029180449&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1309&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1309" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Edwards Lifesciences AG v. CoreValve, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 699 F.3d 1305, 1309 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860ad8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860ad8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
3. Utility
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B222035479688_31}{\*\bkmkend co_anchor_B222035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Finally, Millennium argues that each of the patents lack utility. Given that the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not constitute eligible subject matter and is invalid for lack of enablement, this analysis will be strictly limited to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The threshold of utility \u8220\'3fis not high: An invention is \u8216\'3fuseful\u8217\'3f ... if it is capable of providing some identifiable benefit.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999184753&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Juicy Whip, Inc. v. Orange Bang, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 185 F.3d 1364, 1365 (Fed.Cir.1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To fail the utility requirement, the claims must be totally inoperable. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1992175211&pubNum=0000350&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_350_1571&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1571" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Brooktree Corp. v. Advanced Micro Devices, Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 977 F.2d 1555, 1571 (Fed.Cir.1992)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fTo violate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the claimed device must be totally incapable of achieving a useful result.\u8221\'3f). As previously discussed, Millennium fails to prove this is so here.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B232035479688_31}{\*\bkmkend co_anchor_B232035479688_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium repeats its argument that the asserted claims are not useful because they require definitive dose prediction. Specifically, Millennium asserts that \u8220\'3fit is scientifically impossible to predict or determine the dosage of medication taken by a patient from a metabolite/creatinine ratio\u8221\'3f, the patent lacks utility. (Def.\rquote s Opening Br. (dkt. # 130) 59.) At the outset, Millennium\rquote s argument only succeeds if the court adopts its construction of element (f): \u8220\'3fquantifying the concentration.\u8221\'3f That construction, as addressed earlier, was rejected, since it was founded on the flawed premise that the purpose of the patents was to provide a definitive dosage prediction. In order to provide such a result, the invention would have been required to teach the skilled addressee how to correct or adjust for 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
all
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 sources of variability in urine drug concentrations\u8212\'3fnot just through creatinine normalization.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nowhere in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is this promise made. In fact, the specification expressly acknowledges that the claimed method does not attempt to account for all sources of variability. (\u8242\'3f680 patent at 11:11\u8211\'3f19.) Because Millennium\rquote s utility argument is wedded to the erroneous premise that the invention seeks to predict dosage definitively, when it does not, its argument is rejected.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Contrary to Millennium\rquote s understanding of the\rquote  
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claimed invention is directed to providing a method that allows for improvement in a doctor\rquote s ability to determine whether a patient has been taking medication as prescribed. As addressed earlier, and prior to the claimed invention, the only information gained from urine drug testing was the presence or absence of a drug (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the urine samples could only provide for positive or negative testing result). The invention here does more than this; it provides doctors with information that allows assessment of whether a patient \u8220\'3fhas been using the medication in a manner which is consistent with the prescription.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 3:1719; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 4:50\u8211\'3f54 (emphasis added).) The 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_926_31}{\*\bkmkend co_pp_sp_7903_926_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*926
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 examples in the specification further demonstrate this.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On review of Millennium\rquote s briefing, there is nothing by way of evidence that establishes that the invention could 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 deliver on the new and useful improvements that are stated in the \u8242\'3f680 specification. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999184753&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Juicy Whip,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 185 F.3d at 1365
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This is Millennium\rquote s burden, even more so in the context of summary judgment.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B031312035479688_ID0EDCBM_31}{\*\bkmkend co_fnRef_B031312035479688_ID0EDCBM_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B031312035479688_31" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
31
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 While there is certainly room for argument that the invention could not predict or determine the dosage of medication, evidence proffered to support this point is only applicable had the court adopted Millennium\rquote s claim construction (which it did not). Because Millennium\rquote s claim construction was not adopted\u8212\'3fand since there is no evidence to suggest that the invention does not deliver the claimed improvements over the prior art\u8212\'3fthe \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 meets at least one objective in the specification and satisfies the utility requirement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1984100276&pubNum=0000350&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_350_958&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_958" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Raytheon Co. v. Roper Corp.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 724 F.2d 951, 958 (Fed.Cir.1983)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhen a properly claimed invention meets at least one stated objective, utility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is clearly shown.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860ae8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860ae8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860ae8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860ae8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
C. Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Based on the undisputed positions of the parties on summary judgment and the rulings by the court above, there would appear to be just one arguable issue left for trial as to infringement: whether Millennium\rquote s RADAR Report infringes (f) of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims? Even more refined, there would appear to be a single factual dispute: whether the RADAR Report compares \u8220\'3fa ratio between the concentration of the test metabolite from the patient to the set of known normative data specific to the reference metabolite concentration.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Even as to this narrow issue, Ameritox and Millennium both maintain that there is no material factual dispute, although they would draw opposite legal conclusions from those facts. Contrary to Millennium\rquote s position, however, the undisputed facts would seem to compel the conclusion that it infringes step (f) by use of the RADAR software:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. Millennium is a clinical laboratory that competes in the medication-monitoring industry. (Pl.\rquote s PFOFs (dkt. # 163) \u182\'3f 1.)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
2. Millennium tests urine samples on behalf of doctors, nurses, and other health care providers who prescribe pain medications to treat chronic pain. (Pl.\rquote s PFOFs (dkt. # 163) \u182\'3f\u182\'3f 2.)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
3. Healthcare professionals use Millennium\rquote s services to test specimens and monitor drug levels periodically in their patients to whom medications are prescribed. (Def.\rquote s Resp. to Pl.\rquote s PFOFs (dkt. # 185) \u182\'3f\u182\'3f 3.)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
4. The test results are provided to the requesting doctor via a detailed written report which Millennium calls \u8220\'3fRapid Assessment Drug Adherence Report\u8221\'3f or \u8220\'3fRADAR Report.\u8221\'3f (Pl.\rquote s PFOFs (dkt. # 163) \u182\'3f\u182\'3f 4, 5.)
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Despite these undisputed facts, Millennium still argues in reply that there are two factual distinctions relieving it of any finding of infringement: (1) the health care provider, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Millennium, makes the comparison; and (2) an individual patient\rquote s doctor ultimately decides whether the comparison provided in the RADAR Report has any bearing on assessing a patient\rquote s over or under dosing based on a variety of other independent factors. (Def.\rquote s Reply (dkt. # 183) 62\u8211\'3f65.)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The first distinction would appear contradicted by the undisputed facts, since Millennium contracts and produces the RADAR Report that provides a comparison 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_7903_927_31}{\*\bkmkend co_pp_sp_7903_927_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*927
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the ratio between the concentration of a test metabolite from a patient to a set of normative data, as laid out by the reasoning and facts outlined in Ameritox\rquote s opposition brief. (Pl.\rquote s Opp\rquote n (dkt. # 172) 79\u8211\'3f81.) Indeed, Millennium has provided RADAR Reports providing this comparative data for oxycodone. The court finds it difficult 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to conclude that the skilled addressee (a trained toxicologist, who is familiar with clinical laboratory science) would view this comparative data as falling within the plain and ordinary meaning of element (f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The second distinction morphs with the first and strikes the court as equally meaningless, since the possibility that a doctor 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
may
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ultimately decide to disregard whether an individual falls inside or outside the 95% confidence range established by the RADAR Report does not mean the report does not infringe, any more than a manufacturer of a thermometer could claim its product does not infringe because a doctor may discount the results of a low or high thermometer reading. Similarly, the fact that the \u8220\'3fRADAR Report includes an explicit disclaimer, warning physicians that Millennium makes no interpretations regarding the patient through the RADAR Report\u8221\'3f (Def.\rquote s Reply (dkt. # 183) 72), does not mean the Report did not convey the comparison contemplated by (f) of the \u8242\'3f680 claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Even so, only Millennium actually moved for summary judgment on infringement. Pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_ae0d0000c5150" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Rule of Civil Procedure 56(f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, therefore, the court will give Millennium ten days to advise in a supplemental brief why summary judgment should not be entered against it on the question of infringement of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. No further briefing or oral argument will be allowed except by express order of the court.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860af8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860af8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I109860af8b1011ea80afece799150}{\*\bkmkend co_anchor_I109860af8b1011ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
ORDER
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IT IS ORDERED that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1) defendant Millennium Health, LLC\rquote s motion for summary judgment (dkt. # 126) is GRANTED as to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
895 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and DENIED as to the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 as set forth above;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
2) plaintiff Ameritox, Ltd.\rquote s motion to file sur-reply (dkt. # 192) is GRANTED; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3) Millennium may have until March 2, 2015, to serve and file its response as to why summary judgment should not be entered against it on the question of infringement of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
680 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_31}{\*\bkmkend co_allCitations_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
88 F.Supp.3d 885, 2015 Markman 728501
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00112035479688_31}{\*\bkmkend co_footnote_B00112035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00112035479688_ID0EE4BG_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
When citing to the patent, the number before the colon refers to the column number, and the number or numbers after the colon refer to the line number or line range.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00222035479688_31}{\*\bkmkend co_footnote_B00222035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00222035479688_ID0EF5BG_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The court outlines Ameritox\rquote s patented services here purely for illustrative purposes. Ameritox\rquote s services have no bearing on claims construction or the court\rquote s infringement analysis. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1994070633&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1423&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1423" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Zenith Labs. v. Bristol\u8211\'3fMyers Squibb Co.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 19 F.3d 1418, 1423 (Fed.Cir.1994)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fAs we have repeatedly said, it is error for a court to compare in its infringement analysis the accused product or process with the patentee\rquote s commercial embodiment or other version of the product or process; the only proper comparison is with the claims of the patent.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00332035479688_31}{\*\bkmkend co_footnote_B00332035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00332035479688_ID0ET6BG_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Creatinine is a by-product of muscle metabolism excreted in urine in relatively constant amounts throughout the day. (\u8242\'3f680 patent at 1:63\u8211\'3f2:1.) The patents-in-suit teach calculating a \u8220\'3fdrug metabolite/creatinine ratio\u8221\'3f to adjust for patient hydration; in other words, measuring the value of the drug metabolite and the creatinine in the urine sample and then dividing the former by the latter to obtain a normalized value. (
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 5:34\u8211\'3f39.) According to Ameritox, urine creatinine had never been used successfully to develop a urine drug screen that allowed for comparison and identification of proper and improper use of prescribed medications. (
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See id.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 2:55\u8211\'3f3:3.)
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00442035479688_31}{\*\bkmkend co_footnote_B00442035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00442035479688_ID0E4PAI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Relevant prior art references are outlined at this juncture not only to provide the lens through which a person skilled in the art would construe the claims, but because Millennium makes the representation at the beginning of its brief that \u8220\'3f[t]he patents-in-suit attempt to employ [a] prior art creatinine-normalization method to detect whether a patient is abusing or diverting his/her drug by predicting the dosage of medication taken by the patient.\u8221\'3f (Def.\rquote s Opening Br. (dkt. # 130) 21.) This argument is central to Millennium\rquote s theory that the claims are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00552035479688_31}{\*\bkmkend co_footnote_B00552035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00552035479688_ID0E6XAI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
While Millennium does not move for summary judgment on novelty and obviousness grounds, as evidenced by the George Article, \u8220\'3fin evaluating the significance of additional steps, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 patent-eligibility inquiry and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 novelty inquiry might sometimes overlap.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1304&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1304" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 132 S.Ct. at 1304
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00662035479688_31}{\*\bkmkend co_footnote_B00662035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00662035479688_ID0EQJBI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
For the purposes of this opinion the terms \u8220\'3fskilled addressee\u8221\'3f or \u8220\'3fskilled artesian\u8221\'3f mean persons having ordinary skill in the art (often abbreviated POSITA or PHOSITA).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00772035479688_31}{\*\bkmkend co_footnote_B00772035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00772035479688_ID0EVLBI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Millennium acknowledges in its briefing that the parties dispute the level of ordinary skill required in the art. Millennium further argues, however, that its assertions throughout its brief apply equally to both parties\rquote  proposed characterizations of the level of ordinary skill in the art. This strongly suggests, whether or not Millennium would still technically dispute it, that there is no 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
material
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 difference between the parties\rquote  characterizations of the level of knowledge of the skilled addressee.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00882035479688_31}{\*\bkmkend co_footnote_B00882035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00882035479688_ID0ECFCI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
8
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Given the minor differences among the asserted claims, the court\rquote s construction for \u8220\'3fknown normative data\u8221\'3f and \u8220\'3fquantifying the concentration\u8221\'3f applies equally to all of the asserted claims. This approach, noted in the parties\rquote  briefs, also seems sensible given that both patents share the same specification which informs claim meaning.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00992035479688_31}{\*\bkmkend co_footnote_B00992035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00992035479688_ID0EXNDI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
9
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In the context of construing element (f), the focus is on the theory that the element is seeking to quantify a specific dose of the patient; whereas, the focus of the term in element (b), \u8220\'3fknown normative data,\u8221\'3f was that such data was based on a subject of specific known population where each subject\rquote s prescribed regimen was specifically known.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B010102035479688_31}{\*\bkmkend co_footnote_B010102035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B010102035479688_ID0EI6DI_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
10
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Other courts, along with some judges on the Federal Circuit, have suggested that it is inappropriate to require a party challenging validity on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 grounds to prove invalidity by clear and convincing evidence. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
E.g., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_720&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_720" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 772 F.3d 709, 720 (Fed.Cir.2014)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Mayer, J., concurring) (\u8220\'3fAlthough the Supreme Court has taken up several 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
section
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 cases in recent years, it has never mentioned\u8212\'3fmuch less applied\u8212\'3fany presumption of eligibility. The reasonable inference, therefore, is that while a presumption of validity attaches in many contexts ... no equivalent presumption of eligibility applies in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
section
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 calculus.\u8221\'3f). Although certainly a closer question, the conclusions reached here would not change under either standard.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B011112035479688_31}{\*\bkmkend co_footnote_B011112035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B011112035479688_ID0EKJAK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
11
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A recent decision by Judge Mariana R. Pfaelzer surveys the many patents that have been invalidated since June 2014. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034719813&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_985&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_985" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Cal. Inst. of Tech. v. Hughes Commc\rquote ns,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 No. 2:13\u8211\'3fcv\u8211\'3f07245\u8211\'3fMRP\u8211\'3fHEM, 59 F.Supp.3d 974, 985\u8211\'3f90, 2014 WL 5661290, at *8\u8211\'3f11 (C.D.Cal. Nov. 3, 2014)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
; 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Robert R. Sachs, 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
A Survey of Patent Invalidation Since Alice,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 LAW360, Jan. 13, 2015, http://www.law360.com/articles/604235/a-survey-of-patent-invalidations-since-alice (noting that only 26% of all patents considered in district courts since the 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 decision have survived).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B012122035479688_31}{\*\bkmkend co_footnote_B012122035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B012122035479688_ID0EPWAK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
12
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The representative claim provided:
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
(a) administering a drug providing 6\u8211\'3fthioguanine to a subject having said immune-mediated gastrointestinal disorder; and
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
(b) determining the level of 6\u8211\'3fthioguanine in said subject having said immune-mediated gastrointestinal disorder,
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
wherein the level of 6\u8211\'3fthioguanine less than about 230 pmol per 8x10 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
wherein the level of 6\u8211\'3fthioguanine greater than about 400 pmol per 8x10 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 1295.
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B013132035479688_31}{\*\bkmkend co_footnote_B013132035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B013132035479688_ID0EE4AK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
13
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
While no specific prior art reference outside the four corners of the specification was cited in support, Justice Breyer presumably relied on undisputed facts in the prosecution history (the intrinsic administrative record) to determine whether these steps in the process were inventive in the context of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
section
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035298233&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_841&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_841" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Teva Pharm. USA, Inc. v. Sandoz, Inc.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 135 S.Ct. 831, 841, \u8211\'3f\u8211\'3f\u8211\'3f L.Ed.2d \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f (2015)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3f[W]hen the district court reviews only evidence intrinsic to the patent (the patent claims and specifications, along with the patent\rquote s prosecution history), the judge\rquote s determination will amount solely to a determination of law.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B014142035479688_31}{\*\bkmkend co_footnote_B014142035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B014142035479688_ID0EXCBK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
14
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 John M. Golden, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0426456710&pubNum=0001147&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&fi=co_pp_sp_1147_1790&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_1147_1790" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Flook Says One Thing, Diehr Says Another: A Need for Housecleaning in the Law of Patentable Subject Matter,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 82 
}
{\b0 \cf19 \f4 \i0 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Geo. Wash. L.Rev.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 1765, 1790\u8211\'3f91 (2014)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (providing an-in depth analysis of the 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Court\rquote s explanation of its holding).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B015152035479688_31}{\*\bkmkend co_footnote_B015152035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B015152035479688_ID0EUIBK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
15
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Cf.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Mark A. Lemley, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0370848304&pubNum=0001214&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&fi=co_pp_sp_1214_1279&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_1214_1279" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Point of Novelty,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 105 
}
{\b0 \cf19 \f4 \i0 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
NW. U.L.Rev.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 1253 1279 n. 12 (2011)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3f[T]here is good reason to worry about overbroad patent claims that lock up a wide swath of potential future applications. But the enablement and written description doctrines largely address that concern.\u8221\'3f); 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Michael Risch, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0343014835&pubNum=0001250&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&fi=co_pp_sp_1250_598&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_1250_598" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Everything is Patentable,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 75 
}
{\b0 \cf19 \f4 \i0 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Tenn. L.Rev.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 591, 598\u8211\'3f606 (2008)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (offering examples of patentable subject matter cases that could be reframed through the lens of other patentability doctrines, such as novelty, utility, and adequate disclosure); Anna B. Laakmann, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0379263471&pubNum=0129180&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
An Explicit Policy Lever for Patent Scope,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 19 
}
{\b0 \cf19 \f4 \i0 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Mich. Telecomm. & Tech. L.Rev.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 43, 5354 (2012)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fAlthough they are treated as distinct patentability criteria, the disclosure requirements are conceptually linked both to each other and to the PSM doctrine.\u8221\'3f
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B016162035479688_31}{\*\bkmkend co_footnote_B016162035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B016162035479688_ID0ETRBK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
16
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Among other things, this case is of note for being the first Federal Circuit case using the 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 framework that upheld eligibility of a patent under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B017172035479688_31}{\*\bkmkend co_footnote_B017172035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B017172035479688_ID0EECCK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
17
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Supreme Court recognized the potential for overlap between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1304&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1304" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 132 S.Ct. at 1304
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fthe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 patent-eligibility inquiry and, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 novelty inquiry might sometimes overlap\u8221\'3f). This is also borne out by the legislative history that states expressly that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is an amplification and definition of \u8220\'3fnew\u8221\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. Specifically, the Senate Report associated with the 1952 Patent Statute stated:
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Section
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 sets forth the subject matter that can be patented, \u8216\'3fsubject to the conditions and requirements of this title.\u8217\'3f The conditions under which a patent may be obtained follow, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
section 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 covers the conditions relating to novelty.
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0100971715&pubNum=0001503&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=TV&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
S.Rep. No. 82\u8211\'3f1979
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 1952 U.S.C.C.A.N. 2349, 2399. Later, the same Report observes:
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Section 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, in general, may be said to describe the statutory novelty required for patentability, and includes, in effect, an 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
amplification and definition of \u8216\'3fnew\u8217\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i1 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i1 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
section
}
}
}
{\b0 \cf19 \f4 \i1 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i1 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i1 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i1 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (emphasis added). Of course, this amplification of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 does not mean that 101 and 102 are the same. Perhaps a better analogy is that the sections \u8220\'3foverlap,\u8221\'3f much like two circles in a Venn diagram. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1304&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1304" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 132 S.Ct. at 1304
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B018182035479688_31}{\*\bkmkend co_footnote_B018182035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B018182035479688_ID0EJOCK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
18
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A non-conventional application of an abstract idea will tend not to preempt. This is how Justice Breyer attempted to reconcile 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 with 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Flook
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8212\'3fexplaining that in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Diehr,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 \u8220\'3fthe patentees did not seek to pre-empt the use of [the] equation, but sought only to foreclose from others the use of that equation in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
conjunction with all of the other steps in their claimed process.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1299&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1299" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 132 S. Ct at 1299
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Diehr,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 450 U.S. at 187, 101 S.Ct. 1048
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
) (emphasis added); 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034719813&pubNum=0007903&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_7903_994&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_994" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Cal. Inst. of Tech.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 59 F.Supp.3d at 994, 2014 WL 5661290, at *15
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fAlthough many of these limitations are mathematical algorithms, these algorithms are narrowly defined, and they are tied to a specific error correction process. These limitations are not necessary or obvious tools for achieving error correction, and they ensure that the claims do not preempt the field of error correction. The continuing eligibility of this patent will not preclude the use of other effective error correction techniques. Therefore, all of the asserted claims are patentable.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B019192035479688_31}{\*\bkmkend co_footnote_B019192035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B019192035479688_ID0EAPCK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
19
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Of course, all valid patents foreclose use and preempt. That\rquote s their purpose. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Bernard Chao, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0397896556&pubNum=0111090&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&fi=co_pp_sp_111090_1235&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_111090_1235" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Finding the Point of Novelty in Software Patents,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 28 
}
{\b0 \cf19 \f4 \i0 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Berkeley Tech. L.J.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 1217, 1235\u8211\'3f36 (2013)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fAlmost any claim can be characterized as too broad if the concept is defined narrowly.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B020202035479688_31}{\*\bkmkend co_footnote_B020202035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B020202035479688_ID0EH1CK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
20
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
While the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
680 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 is valid under both 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
112
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
895 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 claims too much under either section. Not restricted to urine screening, the claims in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
895 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 extend to blood, saliva, 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
etc.,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 while at the same time failing to enable one skilled in the art to properly understand the invention. Indeed, there is not only overlap between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 102/103, as Justice Breyer suggests in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 the preemption concern bridges the divide between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
112
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
132 S.Ct. at 1301
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Mark A. Lemley, 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
et al., 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0364493604&pubNum=0001239&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LR&fi=co_pp_sp_1239_1329&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_1239_1329" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Life After Bilski,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 63 
}
{\b0 \cf19 \f4 \i0 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Stan. L.Rev.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 1315, 1329\u8211\'3f30 (2011)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (noting similarities and some of the nuanced differences between enablement and patentable subject matter regarding issues relevant to the time of filing). Even so, the court will follow the Supreme Court\rquote s lead in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and decline an invitation to forego any analysis of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022884686&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Ice57b8d0b52f11dfb5fdfcf739be147c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
895 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1304&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1304" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
132 S.Ct. at 1304
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, while acknowledging that a dispute exists in the Federal Circuit and lower courts as to whether this is necessary. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Compare 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_718&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_718" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 772 F.3d 709, 718 (Fed.Cir.2014)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Mayer, J., concurring) (\u8220\'3fJust as a court must assure itself of its own jurisdiction before resolving the merits of a dispute, it must likewise first assess whether claimed subject matter is even 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
eligible
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 for patent protection before addressing questions of invalidity or infringement.\u8221\'3f) (internal citation omitted), 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034114384&pubNum=0006538&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_6538_995&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_995" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
I/P Engine, Inc. v. AOL Inc.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 576 Fed.Appx. 982, 995\u8211\'3f96 (Fed.Cir.2014)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Mayer, J., concurring) (\u8220\'3fUntil it is determined that claimed subject matter is even 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
eligible
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 for patent protection, a court has no warrant to consider subordinate validity issues such as non-obviousness under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. \u167\'3f 103
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 or adequate written description under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.\u8221\'3f), 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
and SmartGene, Inc. v. Advanced Bio. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027411364&pubNum=0004637&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_4637_51&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_51" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Labs., SA,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 852 F.Supp.2d 42, 51\u8211\'3f52 (D.D.C.2012)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (treating the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 inquiry as the \u8220\'3fthreshold inquiry for patent validity\u8221\'3f), 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
with 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027267394&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1260&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1260" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
MySpace, Inc. v. GraphOn Corp.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 672 F.3d 1250, 1260 (Fed.Cir.2012)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (noting that \u8220\'3fcourts could avoid the swamp of verbiage that is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 ... and insist that litigants initially address patent invalidity issues in terms of the conditions of patentability defenses as the statute provides, specifically 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f\u167\'3f 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
103
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
112
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8221\'3f), 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
and 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026899487&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Dealertrack, Inc. v. Huber,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 674 F.3d 1315, 1335 (Fed.Cir.2012)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Plager, J., concurring in part and dissenting in part) (\u8220\'3f[T]his court should exercise its inherent power to control the processes of litigation and insist that litigants, and trial courts, initially address patent invalidity issues in infringement suits in terms of the defenses provided in the statute: \u8216\'3fconditions of patentability,\u8217\'3f specifically 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f\u167\'3f 102
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
103
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, and in addition 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f\u167\'3f 112
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS251&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
251
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, and not foray into the jurisprudential morass of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 unless absolutely necessary.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B021212035479688_31}{\*\bkmkend co_footnote_B021212035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B021212035479688_ID0EYKDK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
21
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Millennium criticizes Ameritox\rquote s characterization, stating that it merely parrots claim 1 itself, but in more generalized form. Since the court adopted the plain and ordinary meaning of the claims here, Ameritox can hardly be criticized for adopting at step one of 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 precisely what the plain and ordinary meaning of the claims provides.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B022222035479688_31}{\*\bkmkend co_footnote_B022222035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B022222035479688_ID0EPSDK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
22
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Millennium also argues that element (e) of the claimed process in particular\u8212\'3f\u8220\'3fnormalizing the biological sample to adjust for changes in the patient\rquote s hydration status by determining the metabolite/creatinine ratio of the patient\u8221\'3f\u8212\'3fis a natural law that satisfies step one of the 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 analysis. (Pl.\rquote s Opp\rquote n (dkt. # 172) 87.) Whether Millennium intends to advance this theory in the alternative to the abstract nature of the claims as a whole is unclear, but the issue is moot since Millennium succeeds at step one regardless. Moreover, the process of normalizing a urine sample by determining the metabolite/creatinine ratio is not necessarily a natural law, at least on this record. (Orsulak Rebuttal Rept. (dkt. # 118) \u182\'3f\u182\'3f 237\u8211\'3f238 (finding a ratio is not a law of nature).) Creatinine normalization is a process that the inventors considered and then implemented. The ratio is simply the end result. This ratio can hardly be considered a natural law in isolation. The ratio more closely resembles an abstract idea (if at all). Perhaps realizing that its natural law theory was unsound, and inappropriately dissects the claims at step one of the 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 analysis, Millennium makes this very argument in its reply brief. (Def.\rquote s Reply (dkt. # 183) 47.) Moreover, because it was not raised in its opening brief, Millennium has waived this argument, at least for purposes of summary judgment.
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1989090293&pubNum=0000350&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_350_1331&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1331" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Gold v. Wolpert,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 876 F.2d 1327, 1331 n. 6 (7th Cir.1989)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986149101&pubNum=0000350&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_350_922&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_922" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Shlay v. Montgomery,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 802 F.2d 918, 922 n. 2 (7th Cir.1986)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B023232035479688_31}{\*\bkmkend co_footnote_B023232035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B023232035479688_ID0ERNEK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
23
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In this case, what is referred to in the specification actually helps the patentee for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 purposes because the prior art in the \u8220\'3fbackground of the invention\u8221\'3f demonstrates the problems faced by those in the field, since those problems appear to have been significant and solved by solutions specifically tailored in the applicant\rquote s invention. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See generally 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034937126&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1257&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1257" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
DDR,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 773 F.3d at 1257
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (explaining that the patent claimed a specific solution addressing a specific problem that was \u8220\'3frooted in computer technology\u8221\'3f). Indeed, it is the admissions on the face of the specification that assist the patentee in more clearly elucidating the specific problem that is then solved by the patented invention so to meet 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 requirements. This is in contrast to other recent district court decisions that have noted how the admissions in the specification tend to hurt the patentee in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 context. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034377801&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
McRO, Inc. v. Namco Bandai Games Am., Inc.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 No. CV 12\u8211\'3f10327\u8211\'3fGW (FFMx), 2014 WL 4749601, at *11 (C.D.Cal. Sept. 22, 2014)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fAnd the patent\rquote s casual\u8212\'3fand honest\u8212\'3fdescription of the prior art was made at a time when, under the then-prevalent interpretation of the law, such admissions were unlikely to be harmful. One unintended consequence of 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and perhaps of this and other decisions to come, is an incentive for patent applicants to say as little as possible about the prior art in their applications.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B024242035479688_31}{\*\bkmkend co_footnote_B024242035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B024242035479688_ID0E51EK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
24
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In contrast, Dr. Larson testified that aspects of the invention were novel concepts \u8220\'3fwithin the urine screen testing world\u8221\'3f in combination with the other steps of the invention. (Deposition of Michael Larson (\u8220\'3fLarson Dep.\u8221\'3f) (dkt. # 114) 60).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B025252035479688_31}{\*\bkmkend co_footnote_B025252035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B025252035479688_ID0E63EK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
25
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
At step two, 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 expressly requires that the elements be viewed in \u8220\'3fcombination.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_2359&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2359" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
134 S.Ct. at 2359
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fConsidered as an ordered combination [and] ... [v]iewed as a whole.\u8221\'3f). 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See generally 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1880199725&pubNum=0000780&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_780_102&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_102" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Parks v. Booth,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 102 U.S. 96, 102, 26 L.Ed. 54 (1880)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fModern inventions very often consist merely of a new combination of old elements or devices, where nothing is or can be claimed except the new combination.\u8221\'3f). This echoes what was said in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 132 S.Ct. at 1298
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fto consider the three steps as an ordered combination\u8221\'3f). In contrast to 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Millennium has offered nothing in the prior art that indicates that the scientific community would have combined the steps of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
680 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B026262035479688_31}{\*\bkmkend co_footnote_B026262035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B026262035479688_ID0EMYFK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
26
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Similarly, the Haddow Article, which was cited in the specification and formed part of the prosecution history, teaches that although the use of \u8220\'3fcreatinine measurements to reflect hydration\u8221\'3f was known, it adds \u8220\'3fcomplexity and cost when such measurements are applied in routine and clinical practice.\u8221\'3f (Bertholf Rept., Ex. H (dkt. # 209\u8211\'3f8) 562.) This is why \u8220\'3fspecific gravity (relative density) measurements in urine samples from children with asthma\u8221\'3f were used to \u8220\'3fprovide information equivalent to that from creatinine measurements.\u8221\'3f (
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 562\u8211\'3f63.) Moreover, Haddow neither involves drug treatment nor compliance with a prescribed drug regimen, nor any known normative database.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B027272035479688_31}{\*\bkmkend co_footnote_B027272035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B027272035479688_ID0EC3FK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
27
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Further compounding Millennium\rquote s position is that it supplies no meaningful evidence that a scientist would have thought to use creatinine normalization in combination to achieve the new and useful results produced by the invention over the prior art.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B028282035479688_31}{\*\bkmkend co_footnote_B028282035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B028282035479688_ID0EC4FK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
28
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Articles noting these other means are cited in the patent specification itself, and there are even more specific limitations in the dependent claims of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
680 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019780402&pubNum=0004074&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=PA&docFamilyGuid=Iaac693879e2611deabded03f2b83b8a4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
680 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 at 22:19\u8211\'3f48 (claim 4).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B029292035479688_31}{\*\bkmkend co_footnote_B029292035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B029292035479688_ID0E2DHK_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
29
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Millennium, through its technical expert, Dr. Alan Wu, also maintains that the term \u8220\'3fratio\u8221\'3f as used in the asserted claims is indefinite. Ameritox correctly points out that this new invalidity theory was not included in Dr. Wu\rquote s invalidity report, which was due and served on August 11, 2014. Rather, it was first raised in Dr. Wu\rquote s rebuttal infringement report, to which plaintiffs\rquote  expert never had a chance to respond. The court rejects Millennium\rquote s attempt to inject a new invalidity theory through a rebuttal expert report. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022367018&pubNum=0000999&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Ruppert v. Alliant Energy Cash Balance Pension Plan,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 No. 08\u8211\'3fcv\u8211\'3f127, 2010 WL 2518853, at *2 (W.D.Wis. June 18, 2010)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (excluding expert\rquote s new theory offered in deposition for the first time because \u8220\'3fto allow testimony on a matter beyond the scope of the expert report would be improper\u8221\'3f). Regardless, the court has reviewed this new invalidity theory, as well as plaintiff\rquote s sur-reply, and finds that it does not change the analysis under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 112
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, \u182\'3f\u182\'3f 2.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B030302035479688_31}{\*\bkmkend co_footnote_B030302035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B030302035479688_ID0E6SAM_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
30
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
For example, the Federal Circuit noted, as is true here, \u8220\'3f[t]he irony of this situation is that Liebel successfully pressed to have its claims include a jacketless system, but, having won that battle, it then had to show that such a claim was fully enabled, a challenge it could not meet. The motto, \u8216\'3fbeware of what one asks for,\u8217\'3f might be applicable here.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011748793&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Liebel\u8211\'3fFlarsheim,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 481 F.3d at 1380
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B031312035479688_31}{\*\bkmkend co_footnote_B031312035479688_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B031312035479688_ID0EDCBM_31" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
31
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999104074&pubNum=0000506&originatingDoc=Ie2f41dc4bb0411e4a795ac035416da91&refType=RP&fi=co_pp_sp_506_504&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_504" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Schacht v. Wis. Dep\rquote t of Corr.,
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 175 F.3d 497, 504 (7th Cir.1999)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (describing summary judgment as the \u8220\'3fput up or shut up moment\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf22 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf22 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf22 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf22 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf22 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }